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Abstract
Impaired functioning is recognized as a major barrier to recovery among individuals with
psychotic disorders. Research on the role of negative symptomatology on functioning has
identified avolition (i.e. lack of motivation) as being highly correlated with functional outcomes.
However, current measures of avolition fail to consider more intrinsic factors that influence
motivation. There is a need for more nuanced research on the drivers of motivation and their
relationship with functioning to inform the observed relationship between avolition and impaired
functioning. This cross-sectional study uses data obtained from the Prevention and Early
Intervention Program for Psychoses, in London, Ontario. 105 clients of PEPP were assessed
using validated measures of motivational drivers. Multivariate analyses did not show a
statistically significant relationship between the intrinsic drivers of motivation and functional
outcomes. Findings demonstrate the need for updated measures of negative symptoms as well as
the need for further research on motivation and functional outcomes.
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psychotic disorders, schizophrenia, negative symptoms, motivation, avolition, functional
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Chapter 1
1 Introduction
In this chapter, an overview of the thesis topic is provided in Section 1.1 followed by the
research objectives in Section 1.2. Finally, Section 1.3 provides an overview of the structure of
this thesis manuscript as well as the role of the student in the research process.

1.1 Overview of Topic
Defined as a loss of contact with reality, people suffering from psychosis often have difficulties
distinguishing between what is real and what is not 1. These breaks from reality, often with a first
onset during late adolescence and young adulthood 2, lead to disruptions in academic or
professional, personal, and social lives. Psychotic episodes can occur in the context of both
primary psychotic disorders as well as mood disorders with psychotic features. Primary
psychotic disorders are ones in which psychotic symptomology are the primary symptoms, with
disorders such as schizophrenia falling under this category 3-5. Mood disorders with psychotic
features are instances where an individual will have a primary diagnosis of a mood disorder, such
as depression, however they also exhibit psychotic symptoms3-5. Although no direct cause has
been identified as leading to the development of psychosis, a number of possible risk factors
have been identified such as substance use, cognitive deficits and other medical conditions6.
Symptoms of psychotic disorders include delusions and hallucinations, thought disorders, social
withdrawal, and lack of motivation - with the majority of symptoms falling into one of two
categories, positive or negative symptoms 7-9. Positive symptoms consist of hallucinations,
delusions and disturbances of thought, whereas negative symptoms consist of behaviors such as
reduced emotional expressivity and social withdrawal, indicative of a reduction or loss of typical
behaviors 10,11. Although psychotic disorders are considered chronic illnesses, within the last
decade advances have been made in regard to treatment options, often consisting of antipsychotic
medications in conjunction with psychosocial therapeutic interventions 12. Our current
understanding of treating psychosis recognizes the importance of an early intervention approach
12-17

, with past research demonstrating the detrimental effects that a long duration of untreated

psychosis can have on disorder progression and outcome 16.
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Although symptomatic recovery is often achievable with treatment, functional recovery, defined
as a sustained improvement in social and vocational functioning 15, remains more elusive, with
impairments being found in both acute and chronic cases of psychotic disorders18,19. Growing
interest in understanding why functional outcomes are more resistant to treatment has led to a
surge in research attempting to pinpoint correlates of poor functioning. Negative symptoms,
being one of the two key symptom categories defining psychotic symptomology, have
consistently been shown to have a high correlation with functional outcomes 20-25. Recent
evidence has shown that when controlling for other symptoms, such as positive symptoms,
depression, and anxiety, negative symptoms remain a strong correlate of functioning26. Research
has shown that one negative symptom in particular seems to outweigh the others in terms of its
correlation to functional outcomes. Specifically, avolition, defined as a lack of motivation, has
been identified as a strong correlate of functioning 22,23,25,27-30.
Limitations in the methods used to measure negative symptoms may be inflating the contribution
of negative symptoms. Measures of avolition that are currently used, such as the avolition
subscale of the Scale for the Assessment of Negative Symptoms (SANS)31 or the Positive and
Negative Syndrome Scale (PANSS)32, assesses overt behavioral markers rather than intrinsic
motivational states. As such, it is highly possible that the strong, positive correlation observed
between avolition and functioning may be due to the fact that these measures are assessing the
same construct, specifically daily behavioral markers such as personal grooming habits and
occupational/academic ability. Given this high degree of overlap between measures of avolition
and functioning, there is a need for a more in-depth assessment of motivational deficits and their
relationship to functional outcomes to better assess the possible relationship between avolition
and impaired functioning.

1.2 Purpose of Thesis and Research Objectives
The overall goal of this thesis was to examine the relationship between the negative symptom of
avolition and functional outcomes via intrinsic drivers of motivation in a cross-section of people
with primary psychotic disorders. To assess the proposed relationship between motivation and
functioning, we used data from 105 clients of an early psychosis intervention program to
complete the following objectives:
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•

To examine the direct relationship between intrinsic drivers of motivation and overall level of
functioning, adjusting for covariates; and

•

To examine the direct relationship between the intrinsic drivers of motivation and specific
subdomains of functioning, specifically working ability, independent living and self-care,
immediate social networks, and extended social networks, adjusting for possible covariates.

1.3 Thesis Overview and Student Contribution
In the following chapters, I will present a detailed review of the current literature on psychotic
disorders, negative symptoms, and functional outcomes, along with a critical evaluation of
related studies assessing motivation and functioning in people with psychotic disorders (Chapter
2). Then I will present the methods used in this thesis, along with information regarding the data
source, the multiple imputation method used to address missing data, and the variables and
measures used to assess our exposures and outcome (Chapter 3). Subsequently, I will present and
summarize the main findings of our analyses along with the results from our additional
sensitivity analyses undertaken to assess the robustness of our main analyses (Chapter 4).
Finally, I will provide a discussion of our key findings, the overall strengths and limitations of
this thesis, and the implications of this study for future research and clinical care.
The student’s contribution to the current study consisted of selection of the thesis topic, in
collaboration with thesis supervisors, Dr. Arlene G. MacDougall and Dr. Kelly K. Anderson, and
Dr. Ross M.G Norman, the principal investigator of the source study and a member of the thesis
supervisory committee. Study objectives were formulated with insight from the thesis
supervisory committee, and all subsequent phases of the study were developed and produced by
the student, from development of the methodological plan to the preparation of this manuscript,
in consultation with supervisors Dr. MacDougall and Dr. Anderson.
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Chapter 2
2 Literature Review
This chapter will present an overview of psychotic disorders, negative symptoms, and functional
outcomes in Sections 2.1, 2.2 and 2.3 respectively. Issues regarding the measurement of negative
symptoms, individually and with respect to functional outcome assessments, are discussed in
Section 2.4. The search strategy used to identify motivational drivers is reported in Section 2.5,
along with the results from our literature search. Gaps in current knowledge are discussed in
Section 2.6. Lastly, our study rationale and thesis objectives and hypotheses will be presented in
Sections 2.7 and 2.8, respectively.

2.1 Psychosis
2.1.1 Overview
Psychosis can be characterized as disturbances in thought, perception, and behavior 7. As defined
by the Diagnostic and Statistical Manual on Mental Disorders, Fifth Edition (DSM-5) 33 and the
International Classification of Diseases, Tenth Revision (ICD-10) 34, psychosis is not a single
disorder but rather a spectrum 35,36 categorized by a set of key commonly observed features37,
specifically “common and functionally disruptive symptoms of many psychiatric,
neurodevelopmental, neurologic and medical conditions(p715)” 38. A number of disorders fall
within the psychotic spectrum, with the most commonly observed disorders being classified as
primary psychotic disorders. Primary psychotic disorders exhibit psychosis as the defining
feature, with disorders including schizophrenia, schizoaffective disorder, delusional disorder,
schizophreniform disorder and brief psychotic disorder 38. However, an episode of psychosis can
also be observed in other psychiatric conditions such as major depressive disorder and bipolar
disorder. Within these disorders, psychotic symptoms such as hallucinations and delusions may
occur during manic or depressive phases 38. Disorders along the psychosis spectrum differ from
each other by the type, number, and severity of psychotic symptoms present 38. Disorders that
fall closer to the psychotic side of the spectrum would be schizophrenia spectrum disorders,
otherwise considered primary psychotic disorders, whereas disorders that fall closer to the
affective side would be bipolar disorder or major depressive disorder where psychotic symptoms
are secondary to the main affective symptoms consistent with their diagnosis 3-5. This concept of
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psychosis as a spectrum rather than a single disorder with a set of strict clinical criteria is
consistent with population samples in which a large number of individuals report symptoms of
psychosis, however they fail to meet the criteria for the clinical diagnosis of a psychotic disorder
such as schizophrenia 36. Given that psychosis is best represented as a spectrum, with a number
of diagnoses being placed along this spectrum, it is possible for diagnoses and the presentation of
symptoms to evolve over time. This thesis draws on the data of participants who have accessed
care in an early intervention program for psychosis with the majority of participants carrying a
diagnosis of a primary psychotic disorder, including schizophrenia, schizoaffective disorder, and
psychosis not otherwise specified, with a smaller subset of participants diagnosed with bipolar
disorder with psychotic features or depression with psychotic features.

2.1.2 Causes of Psychotic Disorders
Although no direct cause has been identified, there are a number of potential risk factors that
have been identified to increase the likelihood of developing psychosis. A developmental
component has been stated, with models positing that genes involved in neurodevelopment
and/or early environmental insults may lead to aberrant brain development, predisposing one to a
later onset of psychosis6. More recent theories have included the role of social determinants in
the development of psychosis, including factors such as childhood adversity, social isolation, and
migration 6,39. Other possible risk factors identified include alcohol and drug misuse, social
stress, cognitive deficits, childhood trauma, underlying mental illness and other medical
conditions (ex. lupus)6.

2.1.3 Symptom Classification
In diagnosing psychotic disorders such as schizophrenia, a range of commonly presented
symptoms are assessed. Both the DSM-5 and the ICD-10 diagnostic manuals, the two primary
diagnostic manuals used to define and diagnose mental disorders, recognize schizophrenia as
being comprised of features known as positive and negative symptoms7-9. Positive symptoms are
categorized by the presence of hallucinations, delusions, and disorganized or bizarre thought
patterns10. These are collectively referred to as positive symptoms due to them being ‘present’ or
‘added on’ to typical behavior 11. Hallucinations consist of sensory experiences with which one
can see, hear, taste, feel, or smell something without the corresponding external stimulus 38, and
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delusions include pervasive false beliefs that are not based in reality 38,40. In contrast, negative
symptoms refer to a reduction or loss of function 11 and consist of blunted affect, alogia,
avolition, anhedonia, and asociality. Blunted affect refers to reductions in emotional expression
via facial expressions or tone of voice whereas alogia is defined by a reduction in speech 10,41.
Anhedonia refers to a diminished capacity to experience pleasure, regarded as a core feature of
schizophrenia 41.Asociality is defined as a reduction in social initiative and an increase in social
withdrawal due to decreased interest in forming relationships 10,41 whereas avolition refers to a
marked reduction in motivation and motivational behavior 10,11,35. These symptoms can vary in
number and severity depending on the person and their diagnosis. The combination of these
symptoms results in distorted perceptions of reality, and people with lived experiences of
psychosis describe experiences of unshared perceptions, paranoia, and a loss of sense of having a
coherent self 1.

2.1.4 Epidemiology and Burden of Illness of Psychotic Disorders
A first episode of psychosis is typically experienced in between late adolescence and early
adulthood, a period marked by numerous changes both personally and
academically/professionally 6. The onset of psychosis has been found to often result in an
increase in social isolation and detachment from community and peers, discontinuation of
hobbies and school, and impairment in work related activities directly impacting long-term
wellbeing. As a result, an episode of psychosis can be highly disruptive to a person’s life and
negatively impact their growth and development.
The lifetime prevalence of all psychotic disorders has been estimated to be between 3.06% and
3.48% in the general population42. The most commonly occurring psychotic disorder,
schizophrenia, has an estimated lifetime prevalence of between 0.4% and 0.9% within the
general population42-45, low in comparison to other common mental disorders such as major
depression, with an estimate of around 27%46. However, despite its relatively low prevalence,
schizophrenia and other psychotic disorders result in a significant burden to both the healthcare
system and the economy. Schizophrenia is amongst the top 25 leading causes of disability
worldwide and people with psychotic illness have an increased risk of premature mortality when
compared to the general population 47. This increase in mortality is due to an increased risk of

7

suicide along with the numerous co-occurring medical conditions found to be associated with
schizophrenia, as well as the under-detection and under-treatment of these medical conditions 47.
Financial costs associated with schizophrenia are higher in comparison to other chronic mental
and physical health conditions, with both the direct costs to the healthcare system as well as the
indirect costs due to loss of productivity, social service needs, and possible criminal justice
involvement 47,48, resulting in an estimated annual cost of $6.85 billion CAN .
48

2.2 Negative Symptoms in Psychotic Disorders
2.2.1 Historical Overview
As previously stated, negative symptoms consist of processes that are unusual in their reduction
or absence and may result in a decline in function 1,11,41. Schizophrenia has been defined as an
illness of early and progressive degeneration, with negative symptoms representing the illness’
core and possibly the most significant contributing factor in the impaired functioning
experienced by people with psychosis 49. Early descriptions of schizophrenia (1917/1919)
emphasized a disturbance of volition or will as the fundamental underlying process in its
pathology 50,51.
However from the 1950s up until the 1980s, the treatment of schizophrenia was mainly focused
on the alleviation of positive symptoms, namely through the introduction of antipsychotic
medications 52. The distinction between negative and positive symptoms re-introduced by
Andreasen in the 1980s marked the beginning of modern research on the subject53. This brought
about further research and debate on whether the two domains were distinct syndromes. Crow
was one of the first to distinguish between negative and positive syndromes, indicating that they
were syndromes independent of one another and with differing etiologies and prognoses54.
Typically, patients exhibiting predominantly positive symptoms were characterized by good
premorbid functioning, relatively favorable outcomes, acute onset, good response to treatment,
and hyperdopaminergic activity. In contrast, patients exhibiting predominantly negative
symptoms were characterized by poor premorbid functioning, impaired cognition, poor response
to treatment, and structural brain abnormalities 54. More recent factor analyses using measures of
psychotic symptoms have found support for three-factor, five-factor, and even eleven-factor
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models of psychotic symptomology9,55. These findings have indicated symptom categories in
addition to positive and negative symptoms, such as disorganization symptoms, depression, and
anxiety; however, all possible models currently proposed included both positive and negative
symptoms as separate and distinct factor domains. Negative symptoms, in particular, have
consistently been found to load onto a factor separate from positive symptoms, disorganized
symptoms, and affective symptoms, and results from these studies have provided support for the
distinctiveness of negative symptoms and its recognition as being an independent target for
treatment 9.

2.2.2 Current Conceptualization
The current conceptualization of negative symptoms consists of blunting of affect (i.e. reduced
emotional expression), poverty of speech (i.e. alogia), asociality (i.e. apathy or social
withdrawal), avolition (i.e. lack of drive or motivation), and anhedonia (i.e. lack of or diminished
interest, enjoyment, or pleasure from activities) 44,52,56. For example, individuals experiencing
negative symptoms such as blunted affect and/or alogia may seem artificial or mechanical in
movements, with few instances of spontaneous movement, eye contact, or facial expression 57.
Conversations may seem emotionless with few changes in vocal pattern or inflections 57.
Experiences of avolition may be observed through a lack of initiative or self-directed behavior,
whereas others may view the individual as being socially withdrawn or without a sense of caring
57

. Recent research on negative symptoms have also proposed that the symptom domain may be

better represented using a two-factor model, with one factor being ‘diminished expression’
(consisting of blunted affect and alogia) and another being ‘diminished experience/amotivation’
(consisting of avolition, anhedonia and apathy) 8,9,30,35,44,49,58-60. As described by Foussias and
Remington, the diminished experience category involves disturbances of involvement with the
surrounding environment, observed via deficits in drive and pleasure, whereas the diminished
expression category addresses issues regarding expressivity, observed via deficits in affect and
speech49. Outcome differences between both domains have been observed among persons with
schizophrenia. The diminished expression domain being associated with an earlier onset,
diminished cognitive traits and a lower level of education while the diminished experience
domain is related to duration of untreated psychosis (DUP), family history of psychosis, work
status and global functioning59. However, issues regarding the relationship between negative
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symptoms subdomains are still present. Along with research showing differential factor loadings
between the diminished expression and diminished experience domains, these domains also
exhibit a moderate interrelationship, with inter-factor correlation coefficients between 0.47 and
0.57 49. Analyses of the Scale for the Assessment of Negative Symptoms (SANS) have also
demonstrated moderate interrelationships for affective flattening and anhedonia-asociality
subscales (r=0.49 and 0.48, respectively) as well as between alogia and avolition and anhedoniaasociality (r=0.61 and 0.53, respectively) 49. These findings would seem to suggest that although
these domains have distinct phenomenological entities, that they may reflect a common
underlying etiology.
In comparison to positive symptoms, negative symptoms are often associated with a more
chronic and deteriorating course of illness, with the symptoms persisting even after positive
symptoms have been treated and largely reduced 13,44,61,62. Evidence suggests that negative
symptoms contribute to more impaired quality of life and poorer functioning than positive
symptoms 22,24,26,63,64. However, negative symptoms are often not as easily observable and are
harder to identify, unlike positive symptoms which are more easily viewed and are often the
most prominent and troubling symptoms present at the onset of psychosis. For reasons such as
these, positive symptoms were once considered the main defining feature of psychosis and
therefore much research was conducted on positive symptoms being a treatment target of
psychosis. Only recently have more studies been focused on negative symptoms and their impact
on disease progression and outcome.

2.3 Recovery from Psychotic Disorders
2.3.1 Symptomatic vs. Functional Recovery
Although current approaches, such as pharmacological interventions, have aided patients in
achieving some form of symptomatic recovery, it is now understood that recovery from serious
mental illness includes both symptomatic recovery and functional recovery. Symptomatic
recovery refers to sustained improvement in symptoms of psychosis, whereas functional
recovery refers to sustained improvement in social and vocational functioning 15,19,65. Functional
capacity, defined as the ability to perform tasks and activities necessary in daily life, is often
significantly impaired in both the acute and non-acute phases of psychotic illness 15,19,66. Around
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75% of people with a first episode of psychosis achieve symptomatic remission with
antipsychotic medications, however, functional recovery is achieved by only by a minority 20.
Robinson and colleagues found that among a sample of 118 participants diagnosed with
schizophrenia spectrum disorders, around 57% achieved symptomatic remission for 2 years or
longer, whereas only 38% achieved adequate functioning and 14% achieved full
recovery67.Similar findings have been demonstrated by other studies 68,69. With functional
recovery found to lag behind clinical remission, impairments in functional capacity have been
recognized as a major barrier to full recovery among people with primary psychotic disorders20.

2.3.2 Negative Symptoms and Functional Outcome
In recent years, studies have assessed functioning among people with schizophrenia to determine
factors that are strongly associated with poor functional outcomes. Negative symptoms have
been shown to contribute more to impaired functioning than other symptom domains 24,26,66,70.
Rabinowitz and colleagues conducted a study in which they attempted to discern the relative
effect of negative symptoms on functioning, in comparison to other symptom domains24. They
found that both baseline functioning and changes in functioning over time were most strongly
related to negative symptoms, suggesting that functioning and the improvement of functioning is
most strongly related to negative symptoms.
This association between negative symptoms and functional outcomes has consistently been
replicated across a broad range of patient populations, including both first-episode and chronic
psychosis 66. Specifically, studies have shown negative symptoms to be highly correlated with
impairments in occupational functioning, household integration, relationships, and recreational
activities 70,71. Fervaha and colleagues assessed the impact of primary negative symptoms on
functional outcomes, controlling for other psychopathological factors such as positive symptoms,
depression, and anxiety26. Findings showed that even when controlling for these symptoms,
negative symptoms were a significant contributor to the functional impairment seen in patients
with schizophrenia. As well, negative symptoms were found to explain a large portion of the
variance in functional status, even after the variance associated with other clinical variables (e.g.
depression, anxiety, positive symptoms, extra-pyramidal symptoms) had been accounted for.
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Results such as these have highlighted the central role of negative symptoms in functional
outcome.

2.3.3 Avolition and Functioning
With the understanding that negative symptoms are significantly associated with functional
outcomes – more so than any other symptom domain in psychosis – research has shifted towards
understanding the connection between negative symptoms and functional outcomes. Given that
negative symptoms can be classified into separate subdomains, the impact that each of these
domains has on functional outcomes has been investigated. Among the five symptoms that fall
under the category of negative symptoms, the amotivation subdomain has consistently been
found to have the strongest association with functional outcomes.
Foussias and colleagues conducted a study assessing each separate subdomain of negative
symptoms and its contribution to functional impairment25. Among adult outpatients diagnosed
with schizophrenia, they found that the amotivation subdomain of the SANS, consisting of
avolition, anhedonia and asociality, was the sole predictor of functioning accounting for
approximately 74% of the variance in current functioning25. This finding was confirmed in
separate studies using the Apathy Evaluation Scale, a measure of avolition, with similar results
29,72

. To determine whether motivational deficits were strong contributors to poor functioning,

Foussias and colleagues extended past research by assessing the concurrent contributions of
motivational deficits in addition to other negative symptoms and other symptom domains at
baseline on functional outcomes longitudinally73. In a sample of 18 participants diagnosed with
schizophrenia, they found that amotivation was the most influential predictor of functioning, at
baseline as well as at six-month follow-up; with amotivation accounting for 74% and 72% of the
explained variance in functioning, respectively 25,73. In follow up to this study, a 2014 study by
Fervaha and colleagues assessed 754 patients with schizophrenia to determine associations
between selected clinical variables and one-year functional outcomes71. Their analyses identified
several independent predictors, with the strongest being amotivation and neurocognition. A 2015
study by Fervaha and colleagues, assessing the prevalence of motivational deficits and their
impact on community functioning among 166 early intervention participants with a diagnosis of
schizophrenia, found that motivational impairments were found in more than 75% of
participants22. Furthermore, these deficits were the most robust and reliable predictor of
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functional outcomes at baseline and longitudinally, with an independent predictive value that no
other assessed variable exhibited22.
Chang and colleagues conducted a study to examine the direct effect of avolition and other
clinical variables at baseline on one-year functional outcomes in a cohort of people with
schizophrenia27. A number of significant factors were identified to be correlated with functional
outcome at 12 months, including amotivation. However, multiple regression analyses revealed
that the amotivation subdomain and cognitive composite scores were the only independent
factors associated with functioning at 12 months, with amotivation being the most robustly
associated with functioning even after adjusting for cognition, additional negative symptoms,
and other symptom dimensions 27. In a 2015 study by Minchinio and colleagues, the participants
categorized as low functioning all exhibited higher levels of negative symptoms, with avolition
found to be independently associated with functional outcome 23. Amotivation has also been
associated with level of social activity and social outcomes, such as marriage and gaining
competitive employment 74. In fact, studies have been able to clearly separate people based on
their presentation of ‘diminished expression’ (DE) vs ‘diminished experience’ (AA) symptom
severity, with people with high AA severity experiencing worse functioning in all domains, in
addition to more frequent hospitalizations, worse overall psychosis, and social anhedonia 30,70,75.

2.4 Issues in Measurement
Although research has identified negative symptoms, specifically those under the amotivation
subdomain, as being highly associated with functional outcomes, there are concerns regarding
the validity of these findings based on the measures used to assess these variables.

2.4.1 Measurement of Negative Symptoms
Certain criteria should be met for proper measurement of negative symptoms. Such measures
should: (i) assess all domains of negative symptoms while excluding other symptom domains;
(ii) be sensitive to change; (iii) demonstrate good reliability; and (iv) be relatively brief for
administration purposes 76. Most importantly, the measures should assess the symptom itself,
rather than an outcome of that symptom 76. However, current measures of negative symptoms
differ based on their inclusion of negative symptom subdomains. Two of the most widely used
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scales, the Scale for the Assessment of Negative Symptoms (SANS) and the Positive and
Negative Syndrome Scale - Negative Subdomain Scale (PANSS), have a substantial degree of
overlap, but also exhibit significant differences. These scales, in addition to other negative
symptom severity measures, differ in their coverage of the 5 negative symptom domains. As
previously mentioned, the current consensus on negative symptoms views the domain as being
composed of avolition, anhedonia, asociality, alogia and blunted affect 45,52.56. Among the
measures assessed, only the SANS covers all 5 domains. However, the SANS also includes the
domain of inattention, a factor that is no longer considered to be a negative symptom but rather a
symptom of the disorganization symptom domain. The SANS also combines anhedonia and
asociality, two separate negative symptom categories, into a single domain 77. The PANSS
negative symptom subscale contains items outside the currently viewed negative symptom
domains 77. Given that our current understanding of the relationship between the amotivation
subdomain and functional outcomes is reliant on these measures, it is important to examine the
specific factors assessed using these tools.

2.4.2 Overlap in Measures of Avolition and Functioning
Our literature review has shown that the amotivation subdomain, consisting of avolition,
anhedonia and asociality, is the strongest predictor of functional outcomes in individuals with
schizophrenia. Currently, the most commonly used measure of avolition is the SANS
amotivation subdomain. But this measure, in addition to other measures of avolition, has a
degree of conceptual overlap with measures of functional outcomes due to how avolition is
assessed. Measures such as the SANS have items related to avolition that are rated mostly based
on behavior and therefore do not take into account the intrinsic and subjective experiences of
motivation, which may be intact but not directly observable due to other factors 78. When looking
at the avolition subdomain of the SANS, items assess behavior such as personal grooming habits,
with the participant being graded based on the following statement “The patient’s clothes may be
sloppy or soiled, and he or she may have greasy hair, body odor, etc.” (Appendix B). An
assessment of motivation is therefore made based on the individual’s physical appearance,
assuming that a motivated individual would present themselves differently. However, overt
behavioral markers such as personal grooming habits are also included as a marker of functional
outcome. The Role Functioning Scale (RFS)79 is a scale used to measure functional outcomes
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based on four main functioning domains: working productivity, independent living and self-care,
immediate social network, and extended social network. As seen in the RFS Independent Living
and Self-Care subdomain (Appendix C), functioning is assessed based on an individual’s ability
to manage and care for their home and self, with raters making decisions of functional ability
based on whether the participant maintains personal grooming and hygiene habits in addition to
feeding themselves and maintain the cleanliness and upkeep of their household. This overlap in
assessment markers can be observed in other avolition statements such as the “Impersistence at
Work or School”, which states that the person has difficulties seeking or maintaining work,
education, or other meaningful activity. However, assessing the outcome of employment or
education does not necessarily measure one’s motivation to gain employment or education,
which could be hindered due to other factors including systemic barriers such as the stigma
around mental illness 80,81. In fact, this statement more accurately aligns with measures of
vocational functioning, as seen in the Role Functioning Scale Working Productivity subdomain.
As well, the avolition subdomain assessed using these measures have a limited number of items
and therefore this may contribute to the inaccurate measurement of avolition. The SANS only
includes three separate markers of avolition, two of which we have shown to overlap
significantly with measures of functioning.
Measurement issues can also be found within the anhedonia-asociality subdomain of the SANS.
Of the four statements used to assess one’s severity of anhedonia, two focus on sexual activity,
with statements that the individuals may show a decrease sexual interest, activity or enjoyment
and that the person may be unable to form intimate relationships with either the opposite sex or
with family. However, one’s current sexual activity does not necessarily indicate one’s level of
anhedonia. In other words, measuring one’s level of pleasure does not necessarily measure one’s
objective capacity for experiencing pleasure 82, with other factors possibly playing a role in the
ability to form a sexual/intimate relationship, regardless of whether they themselves want to
enjoy said relationship. As well, item 21 asks about the number of friends that the individual has,
with a lack of friends being related to a proposed preference to spend time alone. This purports
that a lack of a large friend network is consistent with a lack of pleasure gained from friendship,
regardless of whether the person wants a larger social group or whether in fact they fail to gain
pleasure from friendships. These SANS anhedonia-asociality items do not directly measure one’s
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ability to experience pleasure but rather the observed behavioral outcomes assumed to be
associated with the ability to experience pleasure, as seen in the SANS avolition subdomain
statements
The validity of current measures of negative symptoms, with an emphasis on
avolition/amotivation subdomains, raises concerns regarding the current evidence base. Here we
discussed the SANS specifically, however other measures of avolition currently used
demonstrate these issues. Past literature has been consistent in their findings of associations
between avolition and functioning, however these associations were drawn from measures that
are limited in their operationalization of negative symptomology. When considering validity,
these measures focus on measuring the outcome of the construct rather than the construct itself;
demonstrating issues in regard to the translation of the symptom constructs into operational
measures 83,84. Construct validity, being the degree to which a measure assesses the construct it
claims to be measuring, would therefore be questioned because the items proposed to measure
avolition do not assess motivation but rather the behavior assumed to be indicative of motivation
84

. When we look specifically at the content of the items proposed to measure these symptom

domains, as seen through the SANS, we see that there are also limitations in how conclusive
these measures are in assessing the construct. External observable characteristics are focused
upon without the assessment of more internal, psychological markers of motivational drive. With
these validity concerns present in measures of negative symptoms in mind, the proposed
relationship between avolition and functioning becomes harder to assess. Given that there is a
limited number of measures that assess avolition, and that current measures demonstrate these
issues in regard to construct validity, there is a need to address more intrinsic aspects of
motivation in regard to their impact on functional outcomes to further elucidate the relationship
between amotivation and functional outcomes.

2.5 Motivational Drivers and Functional Outcomes in Psychosis
2.5.1 Search Strategy
To identify intrinsic factors that drive motivation, we searched through PsycINFO, EMBASE,
and Medline to identify articles examining the association between motivational deficits and
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functioning among individuals with psychotic disorders. Articles examining theories regarding
motivation, avolition, and negative symptoms were assessed.

2.5.2 Cognitive Model of Negative Symptoms
Until recently, little attention had been given to understanding the possible role that motivational
variables have in the development and maintenance of negative symptoms. However, research
regarding the effects of cognitive behavioral therapy (CBT) for people with psychotic disorders
have found that negative symptoms can be targeted in therapy by focusing on factors such as
dysfunctional attitudes, coping style, and self-efficacy 85.
Proposed by Rector, Beck and Stolar, the cognitive model of negative symptoms is a theory
regarding the expression and maintenance of negative symptoms 86. Specifically, the model
proposes that people with schizophrenia often experience cognitive impairments that may hinder
their normal adjustments in social and academic/occupational domains, thus contributing to poor
academic achievement, work performance, and social problems 86,87. These deficits in social and
occupational functioning therefore lead to the formation of dysfunctional attitudes about one’s
abilities, which in turn can reduce one’s motivation or engagement in goal-directed behaviors.
Furthermore, this reduction in engagement and withdrawal from tasks serve as maladaptive
techniques employed to avoid expected poor performance and/or failure. In turn, these
maladaptive techniques strengthen dysfunctional beliefs by limiting one’s ability to participate in
future goal-directed tasks, which may have counteracted poor past experiences. In line with this
theory, it has been proposed that negative symptoms may develop as a result of this cycle of
negative cognitive appraisals regarding one’s self, formed as a response to “threatening
delusional beliefs, perceived social threat, and anticipated failure in tasks and social activities” 86.
Functioning may then become further impaired with the development and maintenance of
negative symptoms.
The model proposes that there are four negative expectancy appraisal domains considered to be
characteristic of negative symptomatology in psychotic disorders that contribute to the
expression and maintenance of negative symptoms. These four domains include having low
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expectancies for pleasure, low expectancies for success, low expectancies for acceptance, and a
perception of limited resources.
Low expectancies for pleasure can be explained as the expectations that people with
schizophrenia often have that they will not gain or will gain very little pleasure for their efforts at
a given activity. Current research supports the theory that people with schizophrenia, in
comparison to non-patient controls, do experience more negative emotions and fewer positive
emotions in daily life, as well as portraying significantly fewer positive and negative facial
expressions in response to emotional stimuli. However, their ability to experience a full range of
emotion is intact, with research showing that this perhaps is a function of their participation in
fewer activities that are likely to elicit pleasant emotions 86.

Figure 2.1 The Cognitive Model of Negative Symptoms86
Low expectancies for success refer to the poor confidence that people with schizophrenia may
have in their ability to perform tasks, and the belief that their performance and abilities are
subpar in instances in which they successfully perform tasks 86. This negative viewpoint affects
their motivation to initiate and follow through with goal directed behaviors 86. This low
expectancy for success has been identified to be a significant factor in the maintenance of
negative symptoms, with individuals’ expectancies for success being positively correlated with
negative symptom severity 88.
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The domain of low expectancies for acceptance refers to the impact that stigma can have on a
person’s motivation and behavior, with previous studies extensively describing the adverse
impact of a schizophrenia diagnosis 86. This may be compounded by symptom distress and
misconstruals by others regarding reasoning behind behavior or lack thereof, that all may lead to
negative beliefs about self-worth.
Finally, the perception of limited resources appraisal domain refers to the dysfunctional beliefs
held by people with schizophrenia about the costs associated with applying energy and effort,
which can lead to passivity and avoidance of activities that require effort 86. This belief in a lack
of available resources however may be a symptom of psychosis itself, given that a number of
studies have found people with schizophrenia possess a diminished cognitive ability for task
relevant cognitive operations. However, this lack of ability may also be exaggerated due to an
inflexible and often pessimistic cognitive view 85.
The cognitive model of negative symptoms demonstrates the psychological influences, or
drivers, that can increase or diminish one’s motivational drive. Negative expectancy appraisals
regarding a person’s ability to gain pleasure, experience success, experience acceptance, and to
gain and develop resources to achieve one’s goals can lead to reductions in motivation and
engagement in both goal-directed behavior and other enjoyable activities, resulting in social
withdrawal and lack of motivation 89.
Use of and support for the cognitive model of negative symptoms has been found in both crosssectional and longitudinal studies 87,88,90-98. A number of studies have found associations between
increased dysfunctional attitudes, such as defeatist performance beliefs, and negative symptoms
in samples of people with schizophrenia 89. Importantly, these associations have been found
even after controlling for other symptom domains, such as depression 22,97.

2.6 Drivers of Motivation
Although research on specific motivational deficits among people with psychotic disorders is
sparse, we identified a number of studies and theories discussing possible processes involved in
motivational drive, as well as a few studies assessing these processes in regard to negative
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symptoms. Motivation has been found to be reliant on a number of processes, revolving around
the ability to anticipate rewards, the hedonic experience of rewards, and the ability to form and
sustain a mental representation of rewards and work towards that future reward by modifying
one’s behavior. Through the use of Rector, Beck, and Stolar’s cognitive model of negative
symptoms and our review of the current evidence base, we identified three psychological factors
found to influence motivational drivers.

2.6.1 Self-efficacy
Self-efficacy has been defined by psychologist Albert Bandura as the extent to which we believe
ourselves capable of successfully performing a given task to produce a desired outcome99.
Perceived self-efficacy refers to an individual’s belief in his or her ability to influence events that
affect the outcome of his or her life 28. Given that self-efficacious beliefs determine how a person
thinks, feels, and behaves, they play a key role in the self-regulation of motivation 99. As belief in
one’s own ability to succeed in tasks is influenced by one’s perceived self-efficacy, it contributes
to the amount of time and effort that one will expend to complete a task, in addition to the
number of obstacles or setbacks tolerated before giving up 94. Self-efficacy beliefs therefore are
thought to be important driving factors in one’s goal setting, willingness to expend effort and
persist at a given activity, and one’s resilience to failure 99.
Self-efficacy beliefs influence one’s causal attributions – people who regard themselves as
highly efficacious attribute their failures to insufficient effort, whereas those who believe
themselves to be inefficacious attributing their failure to their own low ability 99. These causal
attributions affect our level of motivation, our performance, and our affective reactions. People
who have a low perceived self-efficacy avoid or forego certain tasks which may reinforce their
own low expectations, whereas people with a high perceived self-efficacy may be more likely to
view difficult tasks as challenges that they can achieve and learn from 99,100. Although selfefficacy is viewed as a determinant of behavior, it is also possible that one’s experiences of
success due to their own behavior can influence self-efficacy beliefs, suggesting that there may
be a bi-directional relationship between self-efficacy and behavior 99. This is important to note,
given that it would suggest that self-efficacy beliefs are not stagnant and can actively change
given one’s experiences of goal achievement or failure.
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Among individuals with schizophrenia, in both acute and chronic phases of illness, self-efficacy
is reduced in comparison to controls 28,89,101. However, findings have been mixed with respect to
the relationship between self-efficacy and negative symptoms in schizophrenia spectrum
disorders. Numerous studies have found associations between greater self-efficacy and lower
negative symptom severity among people with schizophrenia spectrum disorders
28,85,89,90,94,95,102,103

. A study by Cassar and colleagues used the cognitive model of negative

symptoms to assess possible influences on negative symptom development and maintenance94.
Their findings suggest that low self-efficacy might potentiate negative symptoms, mainly
anhedonia and avolition, through a reduction in expectations of success, efforts to obtain
rewards, confidence in one’s cognitive skills, and a reduced tolerance toward goal obstacles and
aversive experiences. However, it is also important to note that a number of studies have failed to
find a significant relationship between the two variables 96,100,102,104-107. Couture and colleagues
assessed a number of dysfunctional beliefs in relation to the cognitive model of negative
symptoms, with self-efficacy included as a measure of negative expectancy appraisals of one’s
self; however, the authors failed to find a relationship between self-efficacy and negative
symptoms96.
Given the proposed link between negative symptoms, namely avolition, and functional
outcomes, it is possible that a relationship between self-efficacy and functional outcomes also
exists, given that self-efficacious beliefs are a component of motivation. One might expect that
self-efficacy would be the most strongly related motivational driver to the negative symptom
subdomain of avolition, and interventions targeting self-efficacy would be useful for alleviating
avolition and thereby improving functional outcomes. However, few studies have assessed the
role of self-efficacy and functioning in schizophrenia. Pratt and colleagues assessed the role of
self-efficacy as a mediating link between negative symptoms, cognition and premorbid
adjustment, and functioning as measured by psychosocial status among patients diagnosed with
schizophrenia or schizoaffective disorder103. Results showed that although self-efficacy was
found to have a small but significant correlation with premorbid adjustment, negative symptoms,
and functioning, there was no evidence to suggest that self-efficacy mediated the relationship
between these factors103. Specifically, self-efficacy did not mediate the relationship between
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premorbid adjustment or negative symptoms with functioning. However, they did find evidence
to suggest that negative symptoms mediated the relationship between self-efficacy and
functioning103.
A study by Kurtz and colleagues built upon these findings by investigating whether self-efficacy
mediated the relationship between key illness features, such as negative symptoms and cognition,
and performance-based measures of functioning102. There was no association between selfefficacy and functional skills, however they did find a moderating effect of illness insight for the
relationship between self-efficacy and functioning, where at higher levels of insight, self-efficacy
beliefs were linked to measures of functioning. This finding was not present among people with
low insight, providing a possible explanation as to why self-efficacy beliefs, which have been
shown to play a positive role in achievement outcomes of healthy populations 99, have less of a
role in mediating the relationship between key illness features and functioning in schizophrenia.
Studies assessing the mediating role of negative symptoms in the relationship between selfefficacy and functioning have been mixed as well, with some lending support to the mediating
role of negative symptoms 28,93 whereas others have failed to find a mediation effect 95.

2.6.2 Defeatist Performance Beliefs
As the discussion on motivational deficits and their role in the negative symptoms of
schizophrenia has grown in recent years, defeatist performance beliefs (DPB) have received the
most empirical support and been consistently found to be associated with negative symptom
severity and functional outcomes 87. DPB refers to a specific form of defeatist beliefs that
consists of overgeneralized negative conclusions about one’s ability to perform tasks 87.
Consistent with the cognitive model of negative symptoms, defeatist performance beliefs are
considered to fall under the category of dysfunctional attitudes, in which people perceive
themselves to exhibit inferior task performances. These defeatist beliefs form maladaptive
strategies that protect the individual from expected pain and rejection, however they also form
barriers for individuals to engage in constructive activities 98.
DPB regarding the planning and execution of tasks can prevent initiation and engagement in
motivated, goal-directed behavior. Although the role of DPB in schizophrenia has been
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investigated only recently, past research generally focused on the role of dysfunctional attitudes
as a general mechanism underlying motivational and pleasure deficits in people with affective
disorders. Beck and colleagues built upon this work with the development of the cognitive model
of negative symptoms, positing that the development of DPB result in a decreased motivational
drive which may contribute to the decline in functional outcomes in schizophrenia 91.
Specifically, Beck and colleagues theorize that DPB leads people with schizophrenia to a false
sense of safety, whereby one succumbs to the defeatist beliefs and forms dysfunctional attitudes,
and consequently lessen the likelihood of goal-directed behavior further reinforcing their
disengagement from society.
Negative performance beliefs have been endorsed by individuals with chronic schizophrenia to a
greater extent than healthy controls and have also been found to be associated with negative
symptoms 28,98,108. In relation to self-efficacy as a motivational driver, DPB and self-efficacy
have been found to exhibit a moderate inverse correlation to one another, along with each being
significantly associated with negative symptoms when adjusting for one another 89. Crosssectional studies have found that the occurrence of DPB are associated with elevated cognitive
impairments such as deficits in working memory and verbal learning, as well as increased
negative symptom severity 96,97. This positive correlation between DPB and negative symptoms
is found to be independent of positive symptoms, as well as depressive symptoms which are
often found to be closely tied to negative symptomology 28,96,97. Importantly, this relationship
between DPB and negative symptoms is seen to a larger extent with negative symptoms
associated with motivation and pleasure, such as avolition and anhedonia 28,91. A 2011 study by
Couture and colleagues found that when assessing the relationship between DPB and negative
symptom domains, a significant relationship was only observed in regard to the ‘diminished
experience’ domain, referring to the negative symptoms of avolition, anhedonia, and asociality,
thus lending credence to the theory that DPB play an important role in motivational drive96.
Research is limited on the relationship between DPB and functional outcomes. Some studies
have found an association between increased reports of DPB and reduced functioning in people
with schizophrenia. Ventura and colleagues assessed the relationship between dysfunctional
attitudes, including defeatist beliefs, and negative symptoms and found them to be significantly
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correlated with daily functioning, with negative symptoms found to mediate the relationship28.
This association was also demonstrated by Kiwanuka and colleagues 109. As well, Grant and
Beck found an increase in defeatist beliefs to be associated with greater negative symptom
severity, reduced functioning, and decreased neurocognitive performance97. When assessing the
mediational role that DPB may play, they found that DPB were mediators in the relationship
between negative symptoms and functioning. In a study assessing the use of cognitive therapy at
targeting dysfunctional attitudes, Pillny and Lincoln found that a reduction in DPB was
associated with a change in functioning 18 months after treatment, and that the use of cognitive
therapy to target dysfunctional attitudes was effective in improving motivation and functioning
among a sample of individuals with persistent negative symptoms 92.
Although empirical evidence suggests that DPB and functioning are associated, whether they are
mediators in the relationship between negative symptoms and functioning, or rather are mediated
by negative symptoms, is still unclear. Although other cognitive and emotional mechanisms of
negative symptom development and functional outcome decline have been proposed, early
evidence suggests that targeting DPB has the potential to reduce negative symptoms and improve
functional outcomes 91. Campellone and colleagues conducted two meta analyses assessing the
relationship between DPB and negative symptoms and functional outcome in people with
schizophrenia91. Findings demonstrated a small effect size for the relationship between DPB and
negative symptoms, as well as between DPB and functional outcome91.

2.6.3 Anticipatory Pleasure Deficits
Anhedonia has been defined as a diminished capacity to experience pleasant emotions, as well as
a difficulty in experiencing pleasure 49. It is a clinically significant aspect of schizophrenia
falling under the category of negative symptoms and has been found to be relatively stable and
linked with significant impairment in social functioning 82,110. However, current evidence
suggests that people with schizophrenia do not experience a full hedonic deficit. Experimental
studies using a wide range of emotion-evoking stimuli demonstrate that people with
schizophrenia report intact experiences of emotions, both pleasant and unpleasant, and that these
experiences of ‘in the moment’ emotion are equal in intensity compared to healthy controls 49,110112

. Interestingly, studies employing the use of self-report or interview-rated measures of
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anhedonia have found people with schizophrenia tend to report lower levels of trait-like hedonic
experiences 9,110-115. This ‘emotion paradox’ has been assessed by considering what constitutes
the experience of pleasure. According to Klein (1984), pleasure can be divided into two forms,
anticipatory and consummatory, whereby anticipatory pleasure involves motivated behavior and
a desire for a future stimulus whereas consummatory pleasure describes the positive emotion
experiences at satiation 112,116. The Temporal Experience of Pleasure scale developed by Gard
and colleagues116differentiates between anticipatory and consummatory pleasure. Through the
use of this scale, studies have shown that people with schizophrenia experience deficits in selfreported anticipatory pleasure but not consummatory pleasure 116,117. Furthermore, anticipatory
pleasure scores were significantly correlated with behavioral activation, response to rewards,
drive, and assessments of social and family role functioning, whereas consummatory pleasure
was only found to be correlated with physical anhedonia 112,113,116.Foussisas and Remington
proposed that people with schizophrenia experience a diminished capacity to anticipate pleasure
gained by the pursuit or achievement of a goal49. This is indicative of an anticipatory pleasure
deficit, suggesting that anhedonia in schizophrenia is closely related to both motivation and goaldirected behavior. Hedonic impairments, therefore, may be considered one facet of motivational
deficits 82,117, with these findings supporting the two-factor subdomain structure of negative
symptoms with anhedonia and avolition in psychotic disorders being closely related, forming a
distinct subdomain separate from other negative symptoms. Specifically, that psychotic disorder
symptomology includes motivational deficits, with both avolition and anhedonia being
differential expressions of this common underlying process.
Considering the cognitive model of negative symptoms, anticipatory pleasure deficits would
align with the cognitive appraisal domain of low expectancies for pleasure. However, studies
assessing the link between anticipatory pleasure and motivation are limited. In support of the
theory, findings have shown that people with schizophrenia are poor at predicting enjoyment in
the distant future and this strongly influences their motivation to seek out a desired outcome
116,117

. As such, these differences in the experience of wanting versus liking (i.e. anticipatory

pleasure versus consummatory pleasure) may play a strong motivational role in driving
individuals with psychotic disorders to work towards specific stimuli or experiences. A paper by
DaSilva and colleagues examining the association between amotivation and hedonic deficits
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identified a significant correlation between anticipatory pleasure and amotivation82. As well,
Chan and colleagues found, in comparison to patients with no negative symptoms, individuals
who exhibited negative symptoms reported experiencing less anticipatory pleasure but did not
differ in reports on consummatory pleasure118. However, findings from Vignapiano and
colleagues failed to find an association between low motivation and anticipatory pleasure
deficits, demonstrating the mixed findings on the proposed relationship119.
There is a paucity of studies on the relationship between anticipatory pleasure deficits and poor
functioning. Buck and Lysaker found that among a sample of 51 individuals with schizophrenia
spectrum disorder, anticipatory pleasure scores at baseline were correlated with poor social
functioning at six-month follow-up, as well as emotional discomfort and positive symptoms,
however they did not find a correlation between anticipatory pleasure and negative symptoms110.
However, Mote and colleagues conducted a similar study with findings demonstrating the
opposite effect; with anticipatory pleasure scores being negatively correlated with negative
symptoms but no significant relationship with functional outcomes were observed114.

2.7 Knowledge Gap
Although the current evidence base suggests that negative symptoms play a significant role in
functional outcomes, specifically via the avolition/anhedonia subdomain, few studies have
assessed the relationship between functional and psychological drivers of motivation. Instead,
the majority of the studies assessing functional outcome rely solely on measures of avolition that
measure overt behavior as a proxy for motivational level. The concern with this approach is that
rather than measuring the symptoms itself, the behavioral outcome of functional ability is being
assessed. When reviewing the current evidence base, a number of studies were found that
assessed motivational factors such as self-efficacy, defeatist performance beliefs and anticipatory
pleasure deficits. However, these studies were mainly descriptive in nature and did not control
for a full range of potential confounding factors. The few studies that did perform multivariable
analyses did not take in to account a wide range of covariates or potential confounders and
instead focused mainly on symptom variables, such as positive symptoms and depression.
Furthermore, these studies assessed one or two of the identified drivers of motivation, with a
different sample being used with each study. Studies comparing these drivers of motivation and
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the role they play in regard to functional outcomes within the same sample have not been
conducted. Therefore, our current knowledge on the relationship between motivational drivers
and functioning does not consider the role or contributions that other psychosocial and clinical
variables may have.
Additionally, these prior studies often included measures of negative symptoms within their
multivariable models, specifically the negative symptoms that fall within the diminished
experience subdomain, which overlap significantly with measures of functioning. As well, a
number of these studies assessed the role of the identified drivers of motivation in regard to their
indirect effect on functioning, mediated by negative symptoms. However, this approach is
concerning given that measures of negative symptoms, namely avolition subdomains, overlap
with functional measures. As such, we cannot ascertain whether lack of motivation is associated
with poor functioning when both variables are measuring the same overt behavioral markers.
To address these limitations, further study on the role that avolition plays in the development of
functional outcomes using multivariable regression models that include a full range of clinical
and psychosocial confounding factors, without overlapping negative symptom measures, is
warranted.

2.8 Study Rationale and Research Questions
With growing interest in understanding the factors that affect functioning and achieving
functional remission in people with psychosis, the identification of modifiable treatment targets
to improve functionality is important. Given that avolition has been found to be highly correlated
with functioning, the nature of this relationship to functioning needs to be further studied. To
better inform the observed relationship between avolition and impaired functioning and address
past study limitations, there is a need for more nuanced research on the internal driving factors of
motivation and their relationship to functional outcomes. Therefore, the aim of this thesis was to
examine the direct effects of internal drivers of motivation and functioning in a cross-sectional
sample of people with psychotic disorders, in order to address the following research questions:
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1. Is there a relationship between intrinsic, psychological drivers of motivation and
functional outcomes?
2. Is there a difference in the relationship between these motivational drivers and specific
functional domains?

2.9 Thesis Objectives and Hypotheses
2.9.1 Objective 1
Findings from studies assessing the relationship between clinical variables and functional
outcomes in people with psychotic disorders have consistently shown a significant relationship
between negative symptoms, namely avolition, and functioning. However, due to methodological
and validity issues around the assessment of functional outcomes and avolition, findings are
questionable and require the assessment of more intrinsic motivational factors in regard to
functioning. Given the need for (a) a better understanding of how to address negative symptoms,
(b) more intrinsic measures of motivation that may lead to avolition, and (c) treatment targets to
improve functional recovery, we sought to examine and compare the associations between
internal drivers of motivation (self-efficacy, anticipatory pleasure capacity, and defeatist
performance beliefs) and overall functioning among people with a psychotic disorder, without
the confounding effects of avolition and negative symptoms among people with psychotic
disorders.
Hypothesis for Objective 1
We hypothesized that there would be a significant association between each identified internal
driver of motivation and overall functioning. Specifically, we hypothesized that people with
higher self-efficacy, high anticipatory pleasure capacity, and lower defeatist performance beliefs
would experience better overall functioning.

2.9.2 Objective 2
To our knowledge, no study to date has examined the role of multiple motivational drivers on
specific domains of functioning among people with psychosis. Given that functional outcomes
can be divided into separate domains of functioning, we sought to assess the relationships
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between the identified internal drivers of motivation and specific domains of functioning,
specifically working productivity, independent living and self-care, immediate social networks,
and extended social networks in a sample of people with a primary psychotic disorder, adjusting
for demographic and clinical covariates.
Hypothesis for Objective 2
Given the exploratory nature of this objective, we did not have any set hypotheses in regard to
the relationships between each driver of motivation and each functional domain. However, we
expected that there would be observable differences between each driver of motivation within
each functional domain, and between domains and hypothesized that drivers of motivation would
work independently of each other in regard to their impact on functional sub-domains.

29

Chapter 3
3 Methods
3.1 Data Source
This cross-sectional, descriptive study uses data from a shared data repository composed of two
studies that were conducted by an early psychosis intervention (EPI) program, known as the
Prevention and Early Intervention Program for Psychoses (PEPP). Established in 1997, PEPP is
an outpatient mental health treatment programme located at Victoria Hospital, London Health
Sciences Centre in London, Ontario, Canada. PEPP uses a comprehensive approach to treatment
of non-affective psychotic disorders with intensive medical and psychosocial management 14,120.
The PEPP shared data repository consists of (1) a prospective cohort study assessing 10-year
outcomes of individuals who were clients of PEPP; and (2) a cross-sectional study assessing the
magnitude, nature and determinants of negative symptoms of current clients of PEPP. Both
studies received ethics approval from Western University’s Health Sciences Research Ethics
Board (Appendix A). No additional ethics approval was necessary for the purposes of this thesis
as the objectives and methods fell within the scope of the approved protocols.

3.2 Study Setting
PEPP is an integrated clinical and research-based program developed for providing improved
care while simultaneously collecting data on patient outcomes, in order to develop an evidence
base for improving service delivery and our understanding of psychotic disorders and
determinants of outcome 121. PEPP is geared towards the treatment of non-affective psychotic
disorder. At the time of data collection for these studies, PEPP employed strategies to reduce
delays in receiving assessment and treatment by using an open referral policy, with a response
time for assessment occurring rapidly after initial referral 120. Following referral, patients are
screened by a PEPP clinician for symptoms of psychosis. If presenting with such, patients then
undergo a more comprehensive diagnostic assessment by a PEPP psychiatrist. Patients with a
primary psychotic disorder who are between the ages of 16 to 40 years (prior to 2014, patients up
to 50 years of age were eligible), live within the defined catchment area, and have not received
antipsychotic treatment for a period greater than one month are considered eligible and are
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accepted into the program once a consent for assessment and treatment is given 120. Further
information on PEPP services can be found within Appendix D.

3.3 Study Procedure
Data from two studies, titled the “Assessment of 10 Year Outcomes for Clients of the Prevention
and Early Intervention Program for Psychoses (PEPP)” and the “Understanding Negative
Symptoms in Patients of an Early Intervention Program for Psychotic Disorders”, are included
within our data set with the former being referred to as “the 10-year patient outcome study” and
the latter being referred to as “the negative symptom study”.
The 10-year outcome study collected data from patients at baseline, one-year follow-up, fiveyear follow-up and again at 10-year follow-up. This thesis focuses on follow-up assessments
conducted at 10 years, as well as assessments conducted in regard to the negative symptom
study.
Both studies had assessment periods conducted at similar time points (2014-2015) and with
overlapping objectives, namely the assessment of symptomology among individuals with
psychosis, the identification of potential covariates, the evaluation of functioning, quality of life
and other measures of recovery, and a more detailed assessment of negative symptoms and
correlated/predictors of variation in these symptoms. Due to this similarity across study
objectives and procedures, we were able to combine the PEPP data sets for our analyses, for a
total combined dataset of 105 participants; 69 from the 10-year outcome study and 36 from the
negative symptom study.
Participants were provided with a letter of information regarding the nature and purpose of the
study as well as a letter of consent in which they agreed to participate in assessment interviews,
which were scheduled at a time convenient for the participant. Assessment involved the
completion of a battery of clinical and non-clinical outcome measures. Completion of the
assessments were split between two days, separated by one to two weeks. A random number
system was used to determine which measures would be administered to the participant at each
meeting. Written informed consent was obtained from each participant at his/her first assessment
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interview. Demographic information was recorded by means of a demographic questionnaire and
outcome measures were administered using a semi-structured interview format. All clinical
measures were administered by a clinical psychologist or psychiatrist, whereas non-clinical
measures were administered by the research coordinator who was trained and supervised by the
clinical psychologist.
As assessments were completed, the interviewer paid attention to each participant’s demeanor
and energy level. In instances where these factors were diminished, participants were encouraged
to take a break and complete the rest of the assessments at a subsequent session one to two weeks
later.

3.4 Data Set
Access to the PEPP shared data repository was obtained from the principal investigator of the
source studies. The principal investigator was tasked with extracting the requested subset of
variables from the PEPP shared data repository and creating the data set, which was then
transferred for use in the current analyses.
Upon receipt of the data set, SPSS was used to convert the database from SPSS format to SAS
format (.sav to .sas7bdat). SAS version 9.4 122 was then used to ‘clean’ the data. This step
included assessing the distribution of all variables, checking for potential outliers, and re-labeling
and re-coding of variables.

3.5 Variables and Measures
3.5.1 Exposure Variables
Self-Efficacy
Self-efficacy is defined as the confidence one has in their ability to perform a behavior or
specific task 123. To assess self-efficacy, the Generalized Self-Efficacy scale (GSE) was used123.
The GSE is a self-report rating scale consisting of ten items scored using a 4-point Likert scale
ranging from one (Not at all True) to four (Very True). Although self-efficacy is understood to
be domain specific, meaning that one can have more or less firm self-beliefs in different domains
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or situations, the GSE assesses a generalized sense of self-efficacy, which refers to overall
confidence in one’s ability to cope with a wide range of novel and/or demanding tasks 123. This
concept of generalized self-efficacy consists of a two-part cognitive set composed of a sense of
successful agency and pathways 123. The agency component reflects a goal-directed
determination, and the pathways component reflects an ability to plan ways to meet said goals.
The GSE has been used in previous research as a tool to assess self-efficacy and dysfunctional
beliefs about one’s self, and has demonstrated high internal consistency among 127 outpatients
diagnosed with schizophrenia with an ICC value of 0.9 106. It also demonstrated a high test-retest
reliability with ICC values ranging from 0.69 to 0.8 among multiple samples of university
students 123,124. Along with being parsimonious and reliable, the scale has demonstrated both
convergent and discriminant validity.
For the purpose of this thesis, we used the GSE as a measure of one’s overall sense of selfefficacy. Total scores on this measure range from 10 to 40, with higher scores indicative of a
greater sense of self-efficacy. All analyses used the GSE as a continuous variable.
Anticipatory Pleasure Capacity
Anticipatory pleasure is defined as the ability to feel pleasure in regard to future activities,
leading to one having the experience of ‘wanting’ 116. To assess anticipatory pleasure, the
Temporal Experience of Pleasure scale (TEPS) was administered116. The TEPS is an 18 item
self-report measure that assesses two domains of pleasure, being anticipatory pleasure (10
items; e.g. “When I hear about a new movie starring my favourite actor, I can’t wait to see it.”)
and consummatory pleasure (8 items; e.g. “I enjoy taking a deep breath of fresh air when I
walk outside.”). Anticipatory pleasure has been shown to be more closely linked to motivation
and goal-directed behavior, whereas consummatory pleasure has been shown to be closely linked
to satiation 116.Therefore, items written to relate to anticipatory pleasure capacities reflect
pleasure experiences in anticipation of a positive and/or pleasurable stimulus, whereas items
written to relate to consummatory pleasure reflect in-the-moment pleasure in response to a
stimulus. Items were written in regard to both specific and general situations that involved all
five sensory modalities and that focused on the domain of physical pleasure. Items are rated on a
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6-point Likert scale ranging from one (Very False for Me) to six (Very True for Me). Items
related to anticipatory pleasure were used to create a total score for one’s level of anticipatory
pleasure capacity (Appendix E). Total scores on this subscale range from 10 to 60, with higher
scores indicative of a higher capacity for anticipatory pleasure.
The TEPS has demonstrated good internal consistency for the total scale as well as both
subscales for anticipatory and consummatory pleasure, with a Cronbach’s a of 0.87, 0.71 and
.78, respectively, among a sample of 86 persons diagnosed with schizophrenia 125. The test-retest
reliability of the scale and subscales have all been found to be high (r= 0.75; p<0.001) 116. When
tested against scales on pleasure, the TEPS was found to be related but clearly distinguishable
from measures of personality, motivation, and pleasure constructs 116.
As previously stated, individuals with psychotic disorders such as schizophrenia have been found
to have intact consummatory pleasure capacities, with deficits being observed within the
anticipatory pleasure domain. These deficits in anticipatory pleasure have been linked to both
negative symptoms and functional outcomes. For the purpose of this thesis, the anticipatory
pleasure subscale score was used as a measure of anticipatory pleasure capacity and was used as
a continuous variable in all analyses.
Defeatist Beliefs
Defeatist beliefs are defined as overgeneralized negative thoughts about one’s ability to
successfully perform goal directed behavior 97. To assess defeatist beliefs, the Defeatist
Performance Beliefs scale (DPB) was used97. The DPB, a subscale of the Dysfunctional
Attitudes Scale, is a 15-item self-report measure that includes statements concerning one’s
ability to perform tasks and the likelihood of their success (e.g. “If I do not do as well as other
people, it means I am an inferior human being.”) Items are scored using a 7-point Likert scale
ranging from one (Totally Agree) to seven (Totally Disagree).
The DPB has been used in previous studies as a measure of defeatist beliefs in patients with
psychosis 91,96-98 and has demonstrated high internal consistency, with Cronbach’s a of 0.85 96,98.
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For the purpose of this thesis, the total score on the DPB was used as a measure of defeatist
performance beliefs. Total scores on this unidimensional measure range from 15 to 105, with
lower scores being indicative of a high degree of defeatist performance beliefs. All analyses
conducted for this thesis used the DPB as a continuous variable.

3.5.2 Outcome Variable
Functioning
Functioning was assessed using the Role Functioning Scale (RFS)79, consisting of four single
rating scales that are used to evaluate levels of functioning in specific subdomains of everyday
life: (1) Working Productivity; (2) Independent Living and Self-Care; (3) Immediate Social
Network Relationships; and (4) Extended Social Network Relationships. The RFS is scored
using a seven-point Likert scale ranging from one (Minimal Level of Role Functioning) to seven
(Optimal Level of Role Functioning), with each of the seven points on the scales accompanied
by a behaviorally defined description (e.g. Working Productivity, “Productivity severely limited;
often unable to work or adapt to school or homemaking; virtually no skills or attempts to be
productive”.) The total of the four role scores represents a Global Role Functioning Index, with
total scores ranging from 4 to 28. The RFS is administered via a standardized interview, with the
patient being evaluated based on a specified time period, such as the previous week.
The RFS has demonstrated its ability to discriminate accurately between psychiatric and nonpsychiatric patients of varying functional capacity and shows good inter-item (a=0.92), testretest (r=0.85 to 0.92) and inter-rater reliability (t=0.64 to 0.820) 79.
For the purpose of this thesis, we used the RFS Global Index score as an overall assessment of
functioning as well as the subdomain scores for functional capacity in specified areas of
everyday life with higher scores being indicative of better functional outcome. The global index
is a composite measure of the four Likert subscales, with each subscale being a 7-point Likert
scale, and therefore measured ordinally. However, studies and reviews on the use of Likert data
with parametric testing methods have shown that with ordinal measures that have five or more
categories, the data can be treated as continuous 126-129. It has also been demonstrated that
parametric testing methods can be used, which are generally more robust than non-parametric
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testing methods, especially when there is an adequate sample size and if normality is observed
within the data 128,129. Therefore, for the purposes of consistency with our first objective, we
chose to treat the sub-domain scores as continuous for our main analyses.

3.5.3 Potential Covariates
For our main analyses, we controlled for 11 variables that were identified as possible covariates,
and were examined in previous studies, through our literature review with information pertaining
to the relationship between these variables and our exposure and outcome variables presented
below. We were unable to control for four additional variables identified as potential covariates
due to their exclusion from assessments within the negative symptom study, specifically age of
onset, mode of onset, duration of untreated psychosis and premorbid adjustment. Because these
variables were assessed for the 10-year outcome study, we conducted sensitivity analyses on the
subset of data from the 10-year outcome study, including these variables and the other identified
covariates. Information pertaining to these four additional variables and the measures used for
assessment can be found in Appendix F.
Age
Age, measured in years, was assessed at baseline using the demographics questionnaire and was
treated as a continuous variable in our main analyses.
Gender
Gender was assessed at baseline using the demographics questionnaire and was treated as a
dichotomous variable, with possible response items being either Male or Female. In comparison
to males, females have been associated with a higher level of functioning 20,130-132. Furthermore,
females have been associated with greater premorbid adjustment, a shorter duration of untreated
psychosis, and a higher level of education, in comparison to males 130.
Education
Education, measured in years, was assessed using the demographics questionnaire. Higher
education has been shown to be associated with greater functional outcomes 20,47,132. Data on
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years of education was used as a proxy indicator of socio-economic status and treated as a
continuous variable for all analyses.
Length of Treatment
Length of treatment was defined as the length of time, in years, from the date of admission into
PEPP to the date of assessment. These dates were obtained from demographic questionnaires.
Given that our data set contained participants from two separate studies, participants’ length of
treatment varies depending on the study they participated in. In our analyses, length of treatment
was used as a continuous variable.
Perceived Social Support
Social support was assessed using the Interpersonal Support Evaluation List (ISEL)133, a 40-item
self-report measure of perceived social support in which items are dichotomously scored
(Probably True vs. Probably False). The ISEL calculates total scores as well as subdomain scores
assessing four domains of social support including appraisal (10 items; e.g. “There are several
people that I trust to help solve my problems.”), tangible (10 items; e.g. “If I needed help fixing
an appliance or repairing my car, there is someone who would help me.”), self-esteem (10 items;
e.g. “Most of my friends are more interesting than I am.”) and belonging (10 items; e.g. “When I
feel lonely, there are several people that I can talk to.”). Total scores for each subdomain range
from 0 to 10, with higher scores indicative of higher perceived social support within that specific
domain.
The ISEL has been shown to have a high degree of test-retest reliability after a four-month
period (r=0.83) as well as internal consistency (a=0.93), among a sample of 59 individuals with
Bipolar I disorder 134. Social support has been found to be associated with improved functional
outcomes in individuals with schizophrenia 135-137, with the presence of a support system during
early stages of illness predicting better functioning 136.
For the purpose of these analyses, the total perceived social support score was computed using
the total score from each domain of the ISEL, with the total score used as a continuous variable
for all analyses.
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Positive Symptoms
Positive symptoms were assessed using the Scale for the Assessment of Positive Symptoms
(SAPS)138. The SAPS is a 34 item, six-point Likert scale with individual item scores ranging
from zero (Absent) to five (Severe). The SAPS provides both a total score as well as subdomain
scores pertaining to four positive symptoms, including: (1) Hallucinations (7 items; e.g.,
Auditory Hallucinations, “The patient reports voices, noises, or other sounds that no one else
hears.”); (2) Delusions (13 items; e.g. Persecutory Delusions, “The patient believes he is being
conspired against or persecuted in some way.”); (3) Bizarre Behavior (5 items; e.g. Clothing
and Appearance, “The patient dresses in an unusual manner or does other strange things to alter
his appearance.”); and (4) Positive Formal Thought Disorder (9 items; e.g. Derailment, “A
pattern of speech in which ideas slip off track onto ideas obliquely related or unrelated.”).
As a reference point, all items are answered using the time frame of the past month. Total scores
range from 0 to 150, with higher scores indicative of a greater severity of positive symptoms.
Subdomain ratings range from 0 to 65, depending on the subdomain, with higher scores
indicative of a greater severity of that specific positive symptom.
The SAPS has been used frequently in both research and clinical-based settings and has
demonstrated high inter-rater reliability (ICC=0.84) for total summary scores, as well as
moderate to high inter-rater reliability for ratings of each subdomain: hallucinations (ICC=0.91),
delusions (ICC=0.86), bizarre behavior (ICC=0.50), and positive formal thought disorder
(ICC=0.75) 139. Higher positive symptom severity is associated with, poorer social support140, a
greater level of amotivation 141, and poorer functional outcomes in individuals with psychotic
disorders 20,47,72,131,142.
For the purpose of this thesis the total score on the SAPS was used as a measure of positive
symptom severity and was computed by summing the total scores on each subdomain of the
SAPS. This measure was used as a continuous variable for all analyses.
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Negative Symptoms
Negative symptoms were assessed using the Scale for the Assessment of Negative Symptoms
(SANS)31. The SANS is a 25 item, 6-point Likert scale with individual item scores ranging from
zero (Absent) to five (Severe). The SANS provides both a total score as well as subdomain
scores pertaining to five negative symptoms, being: (1) Affective Flattening or Blunting (8
items; e.g., Unchanged Facial Expression, “The patient’s face appears wooden -changes less than
expected as emotional content of discourse changes.”), (2) Alogia (5 items; e.g. Poverty of
Speech, “The patient’s replies to questions are restricted in amount, tend to be brief, concrete,
unelaborated.”), (3) Avolition-Apathy (4 items; e.g. Grooming and Hygiene, “The patient’s
clothes may be sloppy or soiled, and he may have greasy hair, body odour, etc.”), (4)
Anhedonia-Asociality (5 items; e.g. Recreational Interests and Activities, “The patient may
have few or no interests. Both the quality and the quantity of interests should be taken into
account.”) and (5) Attention (3 items; e.g. Social Inattentiveness, “The patient appears
uninvolved or unengaged. He may seem “spacey”.”).
As a reference point, all items are answered using the time frame of the past month 143. Total
scores range from 0 to 100, with higher scores being indicative of a higher severity of negative
symptoms. Subdomain ratings, or global ratings, range from 0 to 25, with higher scores being
indicative of a higher severity of that specific negative symptom.
The SANS has demonstrated moderate to high internal consistencies for the five negative
symptom domains: affective flattening (α=0.81), alogia (α=0.81), attentional impairment
(α=0.84), avolition-apathy (α=0.80), and anhedonia-asociality (α=0.63) 53.
As discussed in chapter two, the SANS total score and subdomain scores demonstrated a high
degree of overlap between negative symptoms and functioning, confirmed in the study dataset
using Pearson correlation coefficients; therefore, SANS scores were excluded from the main
analyses. In the secondary correlation analyses, the SANS total score and subdomain scores were
used as a measure of negative symptoms and were treated as continuous variables.
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Depression and Anxiety
Depressive and anxiety symptoms were assessed using the Profile of Mood States-Short Form
Questionnaire (POMS-SF)144. The POMS-SF is a measure of psychological distress consisting of
37 adjectives (e.g. “Tense”), to which responders are asked to describe how often they
experience the feeling or mood over the course of the past two to three months 144. Responses are
recorded using a five-point Likert scale, with responses ranging from zero (Not at all) to four
(Extremely). Scoring of the POMS-SF yields an overall total mood disturbance score, as well as
scores for six subscales: Fatigue-Inertia (5 items; e.g. “Worn Out”), Vigor-Activity (6 items;
e.g. “Lively”), Tension-Anxiety (6 items; e.g. “Tense”), Depression-Dejection (8 items; e.g.
“Unhappy”), Anger-Hostility (7 items; e.g. “Grouchy”), and Confusion-Bewilderment (5
items; e.g. “Forgetful”).
Total mood disturbance scores range from 0 to 148, and subdomain total scores range as follows:
0 to 20 for Fatigue-Inertia, 0 to 24 for Vigor-Activity, 0 to 24 for Tension-Anxiety, 0 to 32 for
Depression-Dejection, 0 to 28 for Anger-Hostility and 0 to 20 for Confusion-Bewilderment.
Higher scores on the total mood disturbance scale are indicative of greater mood disturbance,
and higher scores on each subdomain reflect greater mood disturbance for each specific domain.
Across multiple samples, the POMS-SF demonstrated high internal consistency (α= 0.76 to 0.95)
with internal consistency estimates being generally similar to or exceeding the original POMS
measure 144. As well, there was a high degree of reliability across samples for each mood state (r
=0.81-0.95) 144.
In individuals with psychosis, both symptoms of depression and anxiety have been found to be
correlated with amotivation 145 and poorer functional outcomes 47,72,146,147. Additionally, the
experience of anxiety has been found to be associated with greater positive symptom severity
and depressive symptoms 147. For the purpose of this thesis, only the Depression-Dejection and
Tension-Anxiety subdomains were used for our analyses, with these variables being treated as
continuous measures.
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Drug Use
Drug use was assessed using the Drug Abuse Screening Test (DAST-20)148. The DAST is a 20item self-report measure of drug use within the last three months, with drug use defined as any
non-medical use of drugs, not including alcohol (e.g. “In the last 3 months, have you used drugs
other than those required for medical reasons?”). Items are scored dichotomously, either Yes or
No, with a score of one for every Yes response, with three items reverse coded. If the responses
for question 1 (i.e. “Have you used drugs other than those required for medical reason?”) and 2
(i.e. “Have you abused prescription drugs?”) were No, then the remaining items were not to be
completed. Total scores on the DAST-20 range from 0 to 20, with higher scores indicative of
greater drug use. Comorbid substance use is considered a major obstacle to recovery amongst
individuals with psychotic disorders 149, with comorbid substance use being associated with an
earlier age of onset, younger age, male gender lower educational attainment and poorer outcomes
such as greater symptom severity and employment and housing instability 149,150.
A cut-off score of 6 or above for the DAST-20 has been recommended for detection of substance
abuse or dependence among 97 psychiatric patients with an Axis 1 mental disorder other than
substance use or dependence (sensitivity, 89-84% and specificity, 68-83%) 151,152. Psychometric
studies on the DAST-20 have shown the DAST-20 to have a high degree of internal consistency
(α =0.74-0.95), and test-retest reliability (ICC=0.71) among a sample of 97 psychiatric patients
with an Axis 1 mental disorder 151.
Although the DAST-20 has a recommended cut-off score (i.e. 6 or above), we chose to group
scores into three categories due to the majority of participants scoring 0 on the DAST-20.
Therefore, DAST-20 was treated as an ordinal variable with responses falling into one of three
possible categories: no drug use (i.e. DAST-20 score of 0), drug use below the cut-off score (i.e.
DAST-20 scores of 1 to 5) or detected drug abuse (i.e. DAST-20 score of 6 or above).
Alcohol Use
Alcohol use severity was assessed using the Alcohol Use Disorders Identification Test
(AUDIT)153. The AUDIT is a 10-item, self-report measure of alcohol use with the reference
point being within the past three months (e.g. “During the last 3 months, how often did you have
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a drink containing alcohol?”). All items are scored on a five-point Likert scale with scores
ranging from zero to four. However, if the response to item one (“During the last three months,
how often did you have a drink containing alcohol?”) is zero, then the remaining nine items are
not to be completed. Total scores on this measure can range from 0 to 40, with higher scores
indicative of a greater severity of alcohol use. As with drug use, excessive alcohol use is
associated with greater symptom severity and a greater risk of mental illness comorbidities
149,150,154

, with individuals diagnosed with a substance use disorder being more likely to have

depression 154.
The AUDIT has shown high internal consistency when used in a sample of 80 individuals with
schizophrenia (α =0.81) 155. As well, an AUDIT cut-off score of eight was shown to have a
sensitivity of 87% and specificity of 90% for detecting alcohol disorders diagnosed by the
Composite International Diagnostic Interview among psychiatric patients (n=71) with a
diagnosis of schizophrenia 155,156.
For the purpose of this thesis, AUDIT scores were treated as categorical, with responses being
grouped into one of three possible categories: no alcohol use (i.e. AUDIT score of 0), use below
the cut-off score (i.e. AUDIT score of 1 to 7), and alcohol abuse (i.e. AUDIT score of 8 or
above).
Medication Adherence
Medication adherence refers to the use of either first or second-generation antipsychotic
medication, and was assessed using the Adherence to Medication Scale, which is a single-item
question pertaining to both the past month and year (i.e. “Based on all available information,
approximately what percentage of time has the patient been taking medication as prescribed?”).
For the purpose of this thesis, we chose to use data pertaining to the past month. Development of
this question was based on results from studies assessing multiple measures of antipsychotic
medication adherence in patients with a first episode of psychosis 157. In individuals with
schizophrenia, non-adherence to antipsychotic medication has been associated with a greater
severity of positive symptoms 137, poorer functional outcomes, alcohol dependence and
substance use disorders 158 and an increased risk of psychiatric hospitalization 158,159.
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The scale is rated by the interviewer based on information obtained from the primary clinician,
case manager, family members, and the patient themselves 157. The estimate is rated using a 4point scale: 1 (0-25%), 2 (26-50%), 3 (51-75%), and 4 (76-100%). Where there was
disagreement between sources on adherence, each case was discussed until a consensus was
reached, however the primary clinician’s estimate on medication adherence carries the most
weight in the decision.
In a comparison study assessing the use of multiple measures of adherence to antipsychotic
medication with a sample of 81 first-episode psychosis patients, Cassidy and colleagues found
that patient reports, pill counts, and clinical reports had good agreement (ICC=0.84), and that all
the measures used were highly correlated to consensus adherence scores (r=0.86 to 0.98)157.
Due to a lack of variability in scores, we chose to treat the variable as dichotomous instead of
categorical. Participant scores were grouped into one of two categories; either less than or equal
to 75% medication adherence (i.e. no medication use to a score of 3) or greater than 75%
medication adherence (i.e. score of 4).

3.6 Missing Data
To determine the extent of missing data within our sample, we first examined (1) the total
number of cases (i.e. participants) with missing observations; (2) the total number of variables
with missing observations; and (3) the number of missing observations for the exposure,
outcome, and potential covariates. Our findings from these analyses are presented in Table 3.1.
Once the extent of missing data had been determined, we examined the pattern of modality of the
missing data. In order to do this, we had to first distinguish between two patterns of missing data
(1) Monotone; and (2) Arbitrary 160,161. A monotone missing data pattern exists if there is a clear,
observable pattern among the variables that are missing. If there is no evident pattern observed,
then the missing data pattern is said to be arbitrary.
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Table 3.1: Missing Data within the Study Sample
Missing Data Assessment

N (Percentage Missing)

Total number of cases with missing data

50 (47.6%)

Total number of variables with missing data

79 (37.3%)

Exposure Variables
Generalized Self Efficacy Score

1 (0.9%)

Temporal Experience of Pleasure- Anticipatory Score

2 (1.9%)

Defeatist Performance Beliefs Score

5 (4.8%)

Outcome Variable
Role Functioning Scale

0 (0.0%)

Work Subscale

0 (0.0%)

Independent Living Subscale

0 (0.0%)

Immediate Social Network Subscale

0 (0.0%)

Extended Social Network Subscale

0 (0.0%)

Potential Covariate Variables
Age

1 (0.9%)

Gender

0 (0.0%)

Education (years)

10 (9.5%)

Age of Onset *

39 (37.14%)

Mode of Onset *

38 (36.19%)

Duration of Untreated Psychosis (weeks) *

38 (36.19%)

Length of Treatment

1 (0.9%)

Premorbid Adjustment Score *

46 (43.81%)

Perceived Social Support Score

2 (1.9%)

Depressive Symptoms

2 (1.9%)

Anxiety Symptoms

2 (1.9%)

Positive Symptoms

0 (0.0%)

Negative Symptoms

0 (0.0%)

Drug Use

1 (0.9%)

Alcohol Use

1 (0.9%)

Medication Adherence
5 (4.8%)
Note: n= Count; Case = Participant; Total number of observations = 105; Total number of variables=221;
* Variables missing large percentages of data were excluded from main analyses
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Once the pattern of modality had been determined, we then determined the mechanism of
missing data, of which there are three possible forms: (1) Missing completely at random
(MCAR); (2) Missing at random (MAR); and (3) Not missing at random (NMAR) 160,162. MCAR
refers to the case where the probability that a value for a particular variable is missing is not
dependent on other measured variables included in the data set and is not related to the value of
the missing variable. MAR refers to instances where the probability of a missing data value for a
specific variable is related to other measured variables in the data set, however it is unrelated to
the value of the missing variable. Finally, NMAR refers to instances where the probability of a
missing data value for a variable is dependent on the value of the missing variable 160,163. From
assessing the dataset, we determined that the pattern of missing data was arbitrary, and that the
mechanism of the missing data was MAR for all data.
When determining the method to handle missing data, we took into account the pattern,
mechanism, and characteristics of the included variables along with our intention to retain the
entire sample (n=105). We therefore decided to use multiple imputation to handle the missing
data present in our data set. Multiple imputation is a method of accounting for missing data
whereby a missing value is imputed multiple times using a set of plausible values sampled from
an imputation model 161.
Multiple imputation involves three stages: (1) Imputing, (2) Analyzing, and (3) Pooling. The
imputing stage is the first step of the procedure where the missing values are imputed m times to
create m complete data set copies. These imputed values are sampled from their predictive
distribution based on the observed data. The next step is to analyze the m completed data sets to
obtain m sets of parameter estimates and corresponding standard errors for the missing values.
These estimates will differ for the m imputed data sets because of the variation introduced during
the imputation phase and must be averaged together to give an overall estimate. Therefore, the
final stage yields parameter estimates, standard errors, and confidence intervals for each of the m
completed data sets that are pooled together to create one overall estimate 160.
To use the multiple imputation method, we had to decide whether we wanted to construct our
imputation model using the multivariate normal method (MVN) or the fully conditional
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specification (FCS) method 161. The multivariate normal method assumes that all variables
included in the imputation model jointly follow a multivariate normal distribution. Therefore, the
imputation stage uses a Bayesian approach to obtain the imputed values from this multivariate
normal distribution, which allows for uncertainty in the estimated model parameters 161. The
fully conditional specification method, also known as the chained equations method, has a more
flexible approach to multiple imputation in that it does not rely on the assumption of multivariate
normality. Conditional distributions are specified for each variable with missing values, and
imputations are generated by estimating each of these conditional distributions in turn using
observed cases for the variable being considered and imputed values for the other variables at
that iteration, thereby imputing the missing values 161. This again allows for uncertainty in the
model parameters. Given that our dataset includes different types of variables (i.e. continuous,
binary, and categorical) we decided to use the FCS method due to its ability to model each
variable using its own distribution, and therefore our regression models can be tailored
appropriately with logistic regression being used for binary variables and linear regression for
continuous variables. In terms of the number of imputations (m), we chose 50 imputations
(m=50) based on the rule of thumb that the number of imputations should be similar to the
percentage of incomplete cases within the data set 164,165.

3.7 Statistical Analyses
All statistical analyses were conducted using SAS version 9.4 122, with all hypothesis testing
using a type 1 error rate set at alpha=0.05, two-tailed.

3.7.1 Descriptive Statistics
Descriptive statistics were summarized for all included participants. Categorical variables were
analyzed using counts and percentages, and continuous variables were analyzed using means and
standard deviations.

3.7.2 Multicollinearity
Given the inclusion of multiple exposure variables and their relation to the construct of
motivation, we assessed for multicollinearity. Multicollinearity describes the situation when one
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variable in a regression model can be linearly predicted from the other variables. It occurs when
two or more variables that are highly correlated with each other are included in the same
regression model and used together to predict the outcome variable 166,167. Issues arise with
multicollinearity due to its impact on effect estimation, with regression coefficients being
imprecisely measured and standard errors being high resulting in wide confidence intervals.
Taken together, these issues make it difficult to reject the null hypothesis 166,167. To assess for the
presence of a high degree of multicollinearity, we used variance inflation factors with the
selected cut-off point of VIF ≥5. The variables were below the selected cut off value, which
indicates a low degree of multicollinearity in our regression models. Although no standard cutoff value for VIF exists, various cut-off values have been used in previous research, ranging
from scores of five to ten 168,169.

3.7.3 Correlation Assessments
To assess the degree of correlation between study variables, we conducted a series of Pearson
correlation matrices to examine the associations between drivers of motivation, avolition, and
functional outcomes.

3.7.4 Analysis: Objective 1
Our first objective was to determine the relationship between indicators of motivation and
functional outcome among people with primary psychotic disorders. We conducted a series of
simple linear regression models to assess the relationship between each exposure and covariate
variable and the outcome variable global functioning. We then constructed a multivariable linear
regression model to assess the relationship between the identified indicators of motivation (selfefficacy, defeatist performance beliefs, and anticipatory pleasure capacity) and the outcome
variable of global functioning, adjusting for potential covariates including age, gender,
education, length of treatment, social support, positive symptoms, depression, anxiety, drug use,
alcohol use and medication adherence. We hypothesized that there would be a positive
association between self-efficacy and functional outcome, a positive association between
anticipatory pleasure capacity and global function, and a negative association between defeatist
performance beliefs and global function, adjusting for potential covariates.
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3.7.5 Analysis: Objective 2
Our second objective was to explore the relationship between these indicators of motivation and
specific subdomains of functioning. First, we conducted a series of simple linear regression
models to assess the relationship between all four subdomains of functioning and each exposure
variable and potential covariates factor. We then constructed four multivariable linear regression
models to assess the relationship between the identified indicators of motivation (self-efficacy,
defeatist performance beliefs, and anticipatory pleasure capacity) and the sub-domains of the
RFS: (i) work, (ii) independent living, (iii) immediate social network, and (iv) extended social
network, adjusting for covariate factors. Each model included the three identified indicators of
motivation as the exposure variables, one of the four subdomains of functioning as the outcome
variable, and the potential covariate variables listed above.

3.7.6 Sensitivity Analyses
We conducted sensitivity analyses to assess the robustness of our findings by repeating
objectives one and two using data from the 10-year outcome study, which contains information
on additional covariate factors not available in the full dataset, specifically age of onset, mode of
onset, duration of untreated psychosis and premorbid adjustment. Using imputed data (n=69) for
participants of the 10-year outcome study that included additional information on covariate
variables that we were unable to include in our main analyses, we repeated our analyses using
these four additional covariates with the variable age being replaced with age of onset. As an
additional sensitivity analysis, given that the RFS is a Likert-based scale, we repeated our
objective one and two analyses using an ordinal logistic regression models treating the outcome
variable as categorical in order to test the robustness of our findings to these methodological
decisions.
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Chapter 4
4 Results
In this chapter, we present descriptive statistics for our study sample in Section 4.1. In Section
4.2, findings from our analyses of the correlation between negative symptoms, avolition, and
functional outcomes are reported. In Section 4.3, the results from our series of simple and
multivariable linear regression analyses assessing the association between motivational drivers
and global functioning, conducted for objective 1, are presented. This is followed by the results
of our series of simple and multivariable linear regression analyses for each subdomain of
functioning conducted for objective 2. In Section 4.5, findings from our sensitivity analyses are
presented.

4.1 Descriptive Statistics
Socio-demographic and clinical characteristic of our study sample are summarized in Table 4.1.
Our sample (n=105) consisted of a higher proportion of males (72%) than females (28%), with a
mean age of 34.2 years (SD=9.9), ranging from 19 to 60 years. The majority of participants were
European American (85%), single (74%) and had a diagnosis of a primary psychotic disorder
(94.3%). Participants were found to be fairly evenly split between being employed (48.6%) and
unemployed (45.7%), with a few participants classified as students (2.9%). The majority of
participants were living with others (68%) and earning an annual income of $29,999 or less
(87%). With respect to the exposure variables within our study sample, participants had a mean
generalized self-efficacy score of 30.9 (SD=5.8), a mean anticipatory pleasure capacity rating of
43.6 (SD=7.9) and a mean defeatist performance belief score of 44.3 (SD=15.8).
Overall, our study sample exhibited moderate to adequate levels of functioning, equivalent to a
score between 20 and 24, with a mean global functioning score of 20.67 (SD=5.29). Total scores
on the RFS ranged from a minimum score of 8 to a maximum score of 28. The distribution of
total RFS scores within the sample (n=105) is shown in Figure 4.1. Functional subdomain
distributions showed that participants had the lowest levels of functioning in the subdomain of
working productivity, with participants scoring a mean of 4.6 (SD=1.8) in comparison to the
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other functional domains of independent living (mean=5.6, SD=1.5), immediate social networks
(mean=5.4, SD=1.4), and extended social networks (mean=4.9, SD=1.5). However, given the
range of possible scores, our study sample exhibited a moderate level of functioning, equivalent
to an individual score of 5, in all four subdomains.

Number of Participants

14
12
10
8
6
4
2
0
8 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Total RFS Score

Figure 4.1 Total RFS Scores for sample (n=105)
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Table 4.1: Descriptive Statistics of Study Sample (n=105)
Characteristic

n (%)

Gender
Male
Female
Ethnicity
European American
African American
Native American
Asian/Pacific Islander
Other
Marital Status
Single
Married/Common Law
Separated/Divorced/Widowed
Living Arrangement
Lives Alone
Lives with Other(s)
Employment Status
Employed
Unemployed
Student
Annual Income
Less than $10,000 to $29,999
$30,000 to $49,999
Primary Diagnosis
Schizophrenia
Affective Disorder(s)
Psychotic Disorder(s)
Drug Use
None
Below Cut off (<6)
Above Cut off (>=6)
Alcohol Use
None
Below Cut off (<6)
Above Cut off (>=6)
Characteristic
Age
Education (in years)
Negative Symptoms
Positive Symptoms
Self-Efficacy
Anticipatory Pleasure Capacity
Defeatist Performance Beliefs
Functioning
Global Functioning Score
Working Productivity
Independent Living and Self-Care
Immediate Social Networks
Extended Social Networks

76 (72.38%)
29 (27.62%)
89 (84.76%)
4 (3.81%)
3 (2.86%)
5 (4.76%)
4 (3.81%)
78 (74.29%)
20 (19.05%)
7 (6.67%)
34 (32.38%)
71 (67.62%)
51 (48.57%)
48 (45.71%)
3 (2.86%)
90 (87.38%)
13 (12.62%)
94 (89.52%)
4 (3.81%)
7 (6.67%)
68 (64.76%)
22 (20.95%)
15 (14.29%)

Mean (SD)
34.16 (9.86)
13.03 (2.04
14.39 (15.79)
11.81 (13.98)
30.95 (5.81)
43.55 (7.92)
44.31 (15.78)

40 (38.10%)
50 (47.62%)
15 (14.29%)
Median
33
13
8
6
31
44
44

Range
19 to 60
8 to17
0 to 62
0 to72
10 to 40
20 to 60
15 to 87

20.67 (5.29)
4.63 (1.78)
5.63 (1.51)
5.44 (1.37)
4.97 (1.53)

22
5
6
6
6

8 to 28
1 to 7
2 to7
2 to 7
2 to 7

Note: n= count; %=percentage; SD=standard deviation; Psychotic Disorder= psychosis not otherwise specified (n=3), brief psychotic disorder
(n=2), psychosis due to medical condition (n=1), and substance induced psychosis (n=1)
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4.2 Correlation Analyses
In order to assess the degree of overlap between measures of negative symptoms and
functioning, we first conducted a series of bivariate correlation analyses. Findings from our
correlation analyses can be found in Table 4.2.1, depicting Pearson correlation coefficients
between total and subdomain scores of the SANS and RFS.
The Pearson correlation coefficient (r) values revealed significant negative associations between
overall functioning and total negative symptoms (r=-0.74, p<0.0001), as well as with the
negative symptom subdomains of Avolition (r=-0.75, p<0.0001) and Anhedonia (r=-0.70,
p<0.0001). Negative Affect (r=-0.54, p<0.0001), Alogia (r=-0.45, p<0.0001), and Attention (r=0.57, p<0.0001) were found to have moderate associations with overall functioning. In
comparing the negative symptom domain of avolition to the functional subdomains, findings
demonstrate that avolition, as measured by the SANS, was more strongly correlated with
working productivity (r=-0.70, p<0.0001) than the other functional subdomains. As well, the
domains of the SANS demonstrated high correlation between negative symptoms subdomains.
Avolition was shown to have a significant positive association with Anhedonia (r=0.755,
p<0.0001). Anhedonia however also exhibited moderate positive associations with Alogia
(r=0.556, p<0.0001) and Attention (r=0.625, p<0.0001) and Negative Affect also had moderate
positive relationships with Alogia (r=0.503, p<0.0001) and Attention (r=0.566, p<0.0001).
Findings from our correlation analyses assessing the relationship between the drivers of
motivation, avolition and functional outcomes can be found in Table 4.2.2. Pearson correlation
coefficients depicted significant negative associations between avolition and self-efficacy (r=0.33, p<0.0001) and anticipatory pleasure capacity (r=-0.13, p<0.0001), respectively although
associations were small. As well, a small yet significant, positive association was found between
avolition and defeatist performance beliefs (r=0.20, p<0.0001).
Correlations between the drivers of motivation and functional outcomes demonstrate small yet
significant relationships between each driver of motivation and overall functioning. However,
differences between the drivers of motivation can be observed through their relationship to
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specific functional subdomains. Self-efficacy was found to have a significant, small association
with both working productivity (r=0.23, p<0.05), and extended social networks (r=0.29, p<0.01).
Anticipatory pleasure capacity was positively associated with both immediate and extended
social networks (r=0.29, p<0.01; r=0.28, p<0.01), respectively, whereas defeatist performance
beliefs were negatively associated with independent living and self-care (r=-0.24, p<0.05), and
immediate social networks (r=-0.26, p<0.01).
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Table 4.2.1: Correlations between Negative Symptoms and Functioning Variables

Negative Symptoms

Negative SANS
Symptoms Total

Avolition
Anhedonia
Blunted
Affect
Alogia
Attention
Functional RFS Total

SANS
Total
-

Functional Outcomes

Avolition Anhedonia Blunted
Affect

Alogia

Attention RFS
Total

WP

ILSC

ISN

0.79*
0.84*
0.66*

0.76*
0.38*

0.41*

-

0.83*
0.92*
-0.74*

0.53*
0.59*
-0.75*

0.56*
0.63*
-0.70*

0.50*
0.57*
-0.54*

0.81*
-0.45*

-0.57*

-

-0.61*

-0.70*

-0.56*

-0.49*

-0.36*

-0.45*

0.87*

-

ILSC

-0.60*

-0.54*

-0.48*

-0.50*

-0.32*

-0.56*

0.79*

0.57*

-

ISN

-0.68*

-0.65*

-0.72*

-0.45*

-0.45*

-0.51*

0.89*

0.66*

0.65*

-

ESN

-0.64*

-0.68*

-0.65*

-0.43*

-0.42*

-0.46*

0.87*

0.69*

0.50*

0.77*

Outcomes WP

Note: SANS Total= Total score on the Scale for the Assessment of Negative Symptoms; RFS Total=Total score on the Role Functioning Scale; WP= Working
Productivity; ILSC=Independent Living and Self-Care; ISN= Immediate Social Networks; ESN=Extended Social Networks; n=105, *=significant at p<0.0001

ESN

-
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Table 4.2.2 Correlations between Drivers of Motivation, Avolition and Functional Outcomes
Motivational Drivers
GSE

TEPS-A

Functional Outcomes
DPB

Avolition RFS

WP

ILSC

ISN

ESN

Total
Motivational GSE
Drivers

-

TEPS-A

0.38**

-

DPB

-0.43**

-0.34**

-

Avolition

-0.33**

-0.13**

0.20**

-

0.24*

0.20*

-0.21*

-

-

WP

0.23*

0.10

-0.13

-

0.87**

-

ILSC

0.12

0.04

-0.24*

-

0.79**

0.57**

-

ISN

0.18

0.29**

-0.26**

-

0.89**

0.65**

0.65**

-

ESN

0.29**

0.28**

-0.13

-

0.87**

0.70**

0.50**

0.77**

Functional

RFS

Outcomes

Total

-

Note: GSE= Generalized Self Efficacy; TEPS-A=Anticipatory Pleasure Capacity; DPB=Defeatist Performance Beliefs; RFS Total=Total score on the Role
Functioning Scale; WP= Working Productivity; ILSC=Independent Living and Self-Care; ISN= Immediate Social Networks; ESN=Extended Social Networks;
n=105, *=significant at p<0.05, **=significant at p<0.01
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4.3 Objective 1
Table 4.3 presents the results of our unadjusted and adjusted linear regression models, with the
exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist performance
beliefs, and the outcome being global functioning.

4.3.1 Exposure Variables
Self-Efficacy
In our unadjusted model, results suggest a positive relationship between self-efficacy and overall
functioning (β=0.22, 95% CI: 0.05 to 0.39) with global functioning scores increasing as selfefficacy scores increased. However, when included within the fully adjusted model, this
relationship was no longer statistically significant (β=0.14, 95% CI: -0.09 to 0.36).
Anticipatory Pleasure Capacity
Findings from our unadjusted models showed a positive relationship between anticipatory
pleasure capacity and overall functioning (β=0.13, 95% CI: 0.00 to 0.26) with global functioning
score increasing as one’s capacity to experience anticipatory pleasure increased. However, this
relationship was no longer statistically significant in the fully adjusted model (β=0.00, 95% CI: 0.15 to 0.15).
Defeatist Performance Beliefs
Results from our unadjusted model showed a negative relationship between defeatist
performance beliefs and overall function (β=-0.07, 95% CI: -0.13 to -0.00) with global
functioning scores decreasing as defeatist performance beliefs increased. However this
relationship was no longer statistically significant when assessed within our fully adjusted model
(β=0.01, 95% CI: -0.07 to 0.09).

4.3.2 Covariate Variables
When assessing our unadjusted model, we see that the variables education, perceived social
support, positive symptoms, depression and drug and alcohol use were associated with overall
functioning. However only education and alcohol use remained statistically significant across our
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models. Specifically, in our unadjusted model, we found level of functioning increased with
increasing years of education (β=0.88, 95% CI: 0.35 to 1.40). In comparison to individuals with
no reported alcohol use, individuals who reported some alcohol use, however not enough to be
considered alcohol abuse, were associated with increased overall functioning (β=3.42, 95% CI:
1.28 to 5.56). However, both of these relationships were attenuated within our fully adjusted
model (β=0.58, 95% CI: 0.07 to 1.09; β=2.35, 95% CI: 0.09 to 4.62).
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Table 4.3: Unadjusted and Adjusted Linear Regression Models with the Outcome of Overall Functional Capacity (n=105)
Variables
Exposure Variables
Self-Efficacy
Anticipatory Pleasure
Defeatist Performance Beliefs
Covariates
Age
Gender
Education (years)
Length of Treatment (years)
Perceived Social Support
Positive Symptoms
Depressive Symptoms
Anxiety Symptoms
Drug Use

Alcohol Use

Medication Adherence

Categorical
Values

Unadjusted Exposure β
(95% CI)

N/A
N/A
N/A

0.22 (0.05 to 0.39) *
0.13 (0.00 to 0.26) *
-0.07 (-0.13 to -0.00) *

Unadjusted Covariate β
(95% CI)

Fully Adjusted β
(95% CI)
0.14 (-0.09 to 0.36)
0.00 (-0.15 to 0.15)
0.01 (-0.07 to 0.09)

N/A
Male
Female
N/A
N/A
N/A
N/A
N/A
N/A
None
Below Cut-Off
Above Cut-Off
None
Below Cut-Off
Above Cut-Off
0-50%

0.06 (-0.05 to 0.16)
-2.13 (-4.39 to 0.13)
Ref.
0.88 (0.35 to 1.40) *
0.08 (-0.10 to 0.26)
0.22 (0.09 to 0.35) *
-0.10 (-0.17 to -0.03) *
-1.56 (-2.96 to -0.16) *
-0.92 (-2.07 to 0.23)
Ref.
2.93 (0.45 to 5.41) *
-2.32 (-5.19 to 0.56)
Ref.
3.42 (1.28 to 5.56) *
2.68 (-0.37 to 5.74)
Ref/

0.04 (-0.09 to 0.18)
-0.94 (-3.43 to 1.55)
Ref.
0.58 (0.07 to 1.09) *
-0.06 (-0.31 to 0.19)
0.14 (-0.05 to 0.34)
-0.05 (-0.12 to 0.02)
0.46 (-1.93 to 2.84)
-0.26 (-2.11 to 1.58)
Ref.
0.98 (-1.77 to 3.72)
-1.97 (-5.28 to 1.33)
Ref.
2.35 (0.09 to 4.62) *
2.32 (-1.04 to 5.68)
Ref.

50-100%

-0.89 (-4.01 to 2.23)

-1.68 (-4.78 to 1.41)

Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables
and covariates; R2=0.33; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable
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4.4 Objective 2
4.4.1 Working Productivity
Table 4.4 contains the results of our unadjusted and fully adjusted linear regression models, with
the exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist
performance beliefs, and the outcome being the functioning subdomain of working productivity.

4.4.1.1 Exposure Variables
Self-Efficacy
In our unadjusted model, results suggest a positive relationship between self-efficacy and
working productivity (β=0.07, 95% CI: 0.01 to 0.13) with scores on the functional subdomain of
working productivity increasing as self-efficacy scores increased. This association remains
largely unchanged in the fully adjusted model; however, the 95% confidence interval now
includes the null value and is no longer statistically significant (β=0.07, 95% CI: -0.00 to 0.15).
Anticipatory Pleasure Capacity
There was no evidence of a relationship between anticipatory pleasure capacity and the
functional subdomain of working productivity (Table 4.4).
Defeatist Performance Beliefs
There was no evidence of a relationship between defeatist performance beliefs and the functional
subdomain of working productivity (Table 4.4).

4.4.1.2 Covariate Variables
When assessing our unadjusted model, we see that the variables education, perceived social
support, positive symptoms, and alcohol use were associated with one’s level of working
productivity. However, these associations were no longer statistically significant within our fully
adjusted model.
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Table 4.4: Unadjusted and Adjusted Linear Regression Models with the Functioning Sub-Domain Outcome of Working
Productivity (n=105).
Variables
Exposure Variables
Self-Efficacy
Anticipatory Pleasure
Defeatist Performance Beliefs
Covariates
Age
Gender
Education (years)
Length of Treatment (years)
Perceived Social Support
Positive Symptoms
Depressive Symptoms
Anxiety Symptoms
Drug Use

Alcohol Use

Medication Adherence

Categorical Values

Unadjusted Exposure β
(95% CI)

N/A
N/A
N/A

0.07 (0.01 to 0.13) *
0.02 (-0.03 to 0.06)
-0.01 (-0.03 to 0.01)

N/A
Male
Female
N/A
N/A
N/A
N/A
N/A
N/A
None
Below Cut-Off
Above Cut-Off
None
Below Cut-Off
Above Cut-Off
0-50%
50-100%

Unadjusted Covariate β
(95% CI)

Fully Adjusted β
(95% CI)
0.07 (-0.00 to 0.15)
-0.02 (-0.08 to 0.03)
0.01 (-0.01 to 0.04)

0.00 (-0.03 to 0.04)
-0.56 (-1.33 to 0.20)
Ref.
0.25 (0.07 to 0.42) *
0.02 (-0.04 to 0.08)
0.06 (0.02 to 0.11) *
-0.04 (-0.06 to -0.01) *
-0.42 (-0.90 to 0.05)
-0.29 (-0.68 to 0.10)
Ref.
0.69 (-0.16 to 1.53)
-0.72 (-1.71 to 0.27)
Ref.
0.82 (0.08 to 1.56) *
0.66 (-0.39 to 1.71)
Ref.
-0.33 (-1.38 to 0.72)

-0.02 (-0.07 to 0.03)
-0.51 (-1.39 to 0.36)
Ref.
0.17 (-0.01 to 0.35)
0.01 (-0.08 to 0.10)
0.04 (-0.03 to 0.11)
-0.02 (-0.05 to 0.00)
0.25 (-0.59 to 1.10)
-0.22 (-0.87 to 0.43)
Ref.
0.08 (-0.88 to 1.04)
-0.58 (-1.73 to 0.58)
Ref.
0.60 (-0.20 to 1.39)
0.63 (-0.54 to 1.81)
Ref.
-0.65 (-1.73 to 0.43)

Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables
and covariates; R2=0.27; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable
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4.4.2 Independent Living and Self-Care
Table 4.5 presents the results of our unadjusted and fully adjusted linear regression models, with
the exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist
performance beliefs, and the outcome being the functioning subdomain of independent living
and self-care.

4.4.2.1 Exposure Variables
Self-Efficacy
There was no evidence of a relationship between self-efficacy and the functional subdomain of
independent living and self-care (Table 4.5).
Anticipatory Pleasure Capacity
There was no evidence of a relationship between anticipatory pleasure capacity and the
functional subdomain of independent living and self-care (Table 4.5).
Defeatist Performance Beliefs
In our unadjusted model, there was a small negative relationship between defeatist performance
beliefs and independent living and self-care (β=-0.02, 95% CI: -0.04 to -0.00) with scores on the
functional subdomain of independent living and self-care decreasing as defeatist performance
belief scores increased. However, when included within the fully adjusted model, this
relationship was no longer statistically significant (β=-0.01, 95% CI: -0.03 to 0.02).

4.4.2.2 Covariate Variables
When assessing our unadjusted model, we see that the variables age, positive symptom severity,
depressive symptoms and drug and alcohol use were associated with independent living and selfcare. However only drug and alcohol use remained statistically significant across our models.
Drug use above the cut-off score, meaning frequent drug use categorized as drug abuse, was
found to have a negative association with independent living and self-care (β=-1.05, 95% CI: 1.86 to -0.23) when compared to those that reported no drug use. Alcohol use below the cut-off
score, meaning some alcohol use however not enough to be considered alcohol abuse, was found
to have a positive association with independent living and self-care (β=0.97, 95% CI: 0.35 to
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1.58) when compared to those that reported no alcohol use. These two relationships were
attenuated within our fully adjusted model (β=-0.98, 95% CI: -1.94 to -0.01; β=0.85, 95% CI:
0.19 to 1.51) but remained statistically significant.
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Table 4.5: Unadjusted and Adjusted Linear Regression Models with the Functioning Sub-Domain Outcome of Independent
Living and Self-Care (n=105).
Variables
Exposure Variables
Self-Efficacy
Anticipatory Pleasure
Defeatist Performance Beliefs
Covariates
Age
Gender
Education (years)
Length of Treatment (years)
Perceived Social Support
Positive Symptoms
Depressive Symptoms
Anxiety Symptoms
Drug Use

Alcohol Use

Medication Adherence

Categorical Values

Unadjusted Exposure β
(95% CI)

N/A
N/A
N/A

0.03 (-0.02 to 0.08)
0.01 (-0.03 to 0.04)
-0.02 (-0.04 to -0.00) *

N/A
Male
Female
N/A
N/A
N/A
N/A
N/A
N/A
None
Below Cut-Off
Above Cut-Off
None
Below Cut-Off
Above Cut-Off
0-50%
50-100%

Unadjusted Covariate β
(95% CI)

Fully Adjusted β
(95% CI)
0.01 (-0.06 to 0.07)
-0.02 (-0.06 to 0.03)
-0.01 (-0.03 to 0.02)

0.04 (0.01 to 0.06) *
-0.51 (-1.16 to 0.14)
Ref.
0.18 (0.03 to 0.33) *
0.04 (-0.01 to 0.09)
0.03 (-0.01 to 0.07)
-0.03 (-0.05 to -0.01) *
-0.40 (-0.80 to -0.00) *
-0.32 (-0.65 to 0.01)
Ref.
0.63 (-0.07 to 1.33)
-1.05 (-1.86 to -0.23) *
Ref.
0.97 (0.35 to 1.58) *
0.35 (-0.52 to 1.23)
Ref.
-0.07 (-0.96 to 0.82)

0.03 (-0.01 to 0.07)
-0.01 (-0.74 to 0.72)
Ref.
0.10 (-0.05 to 0.25)
-0.04 (-0.11 to 0.04)
0.00 (-0.05 to 0.06)
-0.01 (-0.03 to 0.01)
-0.07 (-0.78 to 0.64)
-0.11 (-0.65 to 0.43)
Ref.
0.29 (-0.51 to 1.10)
-0.98 (-1.94 to -0.01) *
Ref.
0.85 (0.19 to 1.51) *
0.58 (-0.41 to 1.57)
Ref.
-0.15 (-1.06 to 0.75)

Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables
and covariates; R2=0.28; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable

63

4.4.3 Immediate Social Networks
Table 4.6 contains the results of our unadjusted and fully adjusted linear regression models, with
the exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist
performance beliefs, and the outcome being the functioning subdomain of immediate social
networks.

4.4.3.1 Exposure Variables
Self-Efficacy
There was no evidence of a relationship between self-efficacy and the functional subdomain of
immediate social networks (Table 4.6).
Anticipatory Pleasure Capacity
Findings from our unadjusted models showed a positive relationship between anticipatory
pleasure capacity and the functional subdomain of immediate social networks (β=0.05, 95% CI:
0.02 to 0.08) with immediate social network scores increasing as one’s capacity to experience
anticipatory pleasure increased. However, this relationship was no longer statistically significant
when assessed within our fully adjusted model (β=0.02, 95% CI: -0.02 to 0.06).
Defeatist Performance Beliefs
In our unadjusted model, results suggest a small negative relationship between defeatist
performance beliefs and immediate social networks (β=-0.02, 95% CI: -0.04 to -0.00) with
scores on the functional subdomain of immediate social networks decreasing as defeatist
performance belief scores increased. However, when included within the fully adjusted model,
this relationship was no longer statistically significant (β=-0.01, 95% CI: -0.03 to 0.02).

4.4.3.2 Covariate Variables
When assessing our unadjusted model, we see that the variables education, perceived social
support, positive symptom severity and alcohol use were associated with the functional domain
of immediate social networks. However, only education, perceived social support and alcohol
use remained statistically significant across models. In both our unadjusted and fully adjusted
linear regression models, education was found to be associated with the functional subdomain of
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immediate social networks (β=0.23, 95% CI: 0.10 to 0.37; β=0.16, 95% CI: 0.03 to 0.30) with
immediate social network scores increasing as years of education increased. As with education,
in both our unadjusted and fully adjusted linear regression models, perceived social support was
found to be associated with the functional subdomain of immediate social networks (β=0.07,
95% CI: 0.03 to 0.10; β=0.06, 95% CI: 0.01 to 0.11) with immediate social network scores
increasing as perceived social support increased. Alcohol use below the cut-off was found to
have an association with immediate social networks (β=0.90, 95% CI: 0.34 to 1.46; β=0.60, 95%
CI: 0.01 to 1.20) when compared to those that reported no alcohol use. Findings demonstrated
that the relationships between this functional domain and education and alcohol usage were
attenuated when covariate variables were included within the regression model.
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Table 4.6: Unadjusted and Adjusted Linear Regression Models with the Functioning Sub-Domain Outcome of Immediate
Social Networks (n=105).
Variables
Exposure Variables
Self-Efficacy
Anticipatory Pleasure
Defeatist Performance Beliefs
Covariates
Age
Gender
Education (years)
Length of Treatment (years)
Perceived Social Support
Positive Symptoms
Depressive Symptoms
Anxiety Symptoms
Drug Use

Alcohol Use

Medication Adherence

Categorical Values

Unadjusted Exposure β
(95% CI)

N/A
N/A
N/A

0.04 (-0.00 to 0.09)
0.05 (0.02 to 0.08) *
-0.02 (-0.04 to -0.00) *

N/A
Male
Female
N/A
N/A
N/A
N/A
N/A
N/A
None
Below Cut-Off
Above Cut-Off
None
Below Cut-Off
Above Cut-Off
0-50%
50-100%

Unadjusted Covariate β
(95% CI)

Fully Adjusted β
(95% CI)
-0.00 (-0.06 to 0.05)
0.02 (-0.02 to 0.06)
-0.01 (-0.03 to 0.01)

0.01 (-0.02 to 0.04)
-0.40 (-0.99 to 0.20)
Ref.
0.23 (0.10 to 0.37) *
0.03 (-0.02 to 0.07)
0.07 (0.03 to 0.10) *
-0.02 (-0.04 to -0.00) *
-0.34 (-0.71 to 0.02)
-0.18 (-0.48 to 0.13)
Ref.
0.63 (-0.03 to 1.29)
-0.44 (-1.20 to 0.33)
Ref.
0.90 (0.34 to 1.46) *
0.53 (-0.27 to 1.33)
Ref.
-0.28 (-1.20 to 0.53)

0.00 (-0.03 to 0.04)
-0.11 (-0.75 to 0.54)
Ref.
0.16 (0.03 to 0.30) *
0.01 (-0.06 to 0.07)
0.06 (0.01 to 0.11) *
-0.01 (-0.03 to 0.01)
0.21 (-0.40 to 0.83)
0.07 (-0.41 to 0.55)
Ref.
0.09 (-0.63 to 0.80)
-0.30 (-1.16 to 0.56)
Ref.
0.60 (0.01 to 1.20) *
0.32 (-0.55 to 1.20)
Ref.
-0.46 (-1.27 to 0.35)

Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables
and covariates; R2=0.34; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable
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4.4.4 Extended Social Networks
Table 4.7 contains the results of our unadjusted and fully adjusted linear regression models, with
the exposure variables being self-efficacy, anticipatory pleasure capacity and defeatist
performance beliefs, and the outcome being the functioning subdomain of extended social
networks.

4.4.4.1 Exposure Variables
Self-Efficacy
In our unadjusted model, results suggest a positive relationship between self-efficacy and the
functional subdomain of extended social networks (β=0.07, 95% CI: 0.02 to 0.12) with extended
social networks scores increasing as self-efficacy scores increased. However, when included
within the fully adjusted model, this relationship was no longer statistically significant (β=0.06,
95% CI: -0.01 to 0.12).
Anticipatory Pleasure Capacity
Findings from our unadjusted models showed a positive relationship between anticipatory
pleasure capacity and the functional subdomain of extended social networks (β=0.05, 95% CI:
0.02 to 0.09) with extended social network scores increasing as one’s capacity to experience
anticipatory pleasure increased. However, this relationship was no longer statistically significant
when assessed within our fully adjusted model (β=0.02, 95% CI: -0.02 to 0.06).
Defeatist Performance Beliefs
There was no evidence of a relationship between defeatist performance beliefs and the functional
subdomain of extended social networks (Table 4.7).

4.4.4.2 Covariate Variables
When assessing our unadjusted model, we see that the variables gender, education, perceived
social support, and drug and alcohol use were associated with the functional domain of extended
social networks. However only education remained statistically significant across models. In
both our unadjusted and fully adjusted linear regression models, education was found to be
significantly associated with the functional subdomain of extended social networks (β=0.21, 95%
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CI: 0.06 to 0.37; β=0.15, 95% CI: 0.01 to 0.30) with extended social network scores increasing
as years of education increased. Findings demonstrated that this relationship was attenuated
when covariate variables were included within the regression model.
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Table 4.7: Unadjusted and Adjusted Linear Regression Models with the Functioning Sub-Domain Outcome of Extended
Social Networks (n=105).
Variables
Exposure Variables
Self-Efficacy
Anticipatory Pleasure
Defeatist Performance Beliefs
Covariates
Age
Gender
Education (years)
Length of Treatment (years)
Perceived Social Support
Positive Symptoms
Depressive Symptoms
Anxiety Symptoms
Drug Use

Alcohol Use

Medication Adherence

Categorical Values

Unadjusted Exposure β
(95% CI)

N/A
N/A
N/A

0.07 (0.02 to 0.12) *
0.05 (0.02 to 0.09) *
-0.01 (-0.03 to 0.01)

N/A
Male
Female
N/A
N/A
N/A
N/A
N/A
N/A
None
Below Cut-Off
Above Cut-Off
None
Below Cut-Off
Above Cut-Off
0-50%
50-100%

Unadjusted Covariate β
(95% CI)

Fully Adjusted β
(95% CI)
0.06 (-0.01 to 0.12)
0.02 (-0.02 to 0.06)
0.01 (-0.01 to 0.04)

0.01 (-0.02 to 0.04)
-0.66 (-1.31 to -0.01) *
Ref.
0.21 (0.06 to 0.37) *
-0.00 (-0.05 to 0.05)
0.06 (0.02 to 0.10) *
-0.02 (-0.04 to 0.00)
-0.39 (-0.80 to 0.01)
-0.13 (-0.47 to 0.20)
Ref.
0.99 (0.27 to 1.71) *
-0.11 (-0.95 to 0.73)
Ref.
0.74 (0.11 to 1.36) *
1.14 (0.25 to 2.03) *
Ref.
-0.20 (-1.11 to 0.70)

0.02 (-0.02 to 0.06)
-0.30 (-1.03 to 0.42)
Ref.
0.15 (0.01 to 0.30) *
-0.04 (-0.12 to 0.03)
0.04 (-0.02 to 0.10)
-0.01 (-0.03 to 0.01)
0.06 (-0.63 to 0.45)
-0.00 (-0.54 to 0.53)
Ref.
0.52 (-0.28 to 1.32)
-0.12 (-1.09 to 0.84)
Ref.
0.30 (-0.36 to 0.97)
0.79 (-0.20 to 1.77)
Ref.
-0.42 (-1.33 to 0.48)

Note: Unadjusted refers to simple linear regression models; Fully Adjusted refers to multivariable regression models adjusted for additional exposure variables
and covariates; R2=0.30; *Indicates findings significant at p<0.05; β=Beta Coefficient; CI= Confidence Interval; Ref=Reference Group; N/A=Not Applicable
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4.5 Sensitivity Analyses
4.5.1 Sensitivity Analyses Using Additional Variables
4.5.1.1 Objective 1
Results from our sensitivity analyses including an additional four variables, being age of onset,
mode of onset, duration of untreated psychosis and premorbid adjustment, were consistent with
our main analyses in that no significant relationship was observed between our exposure
variables and overall functioning and effect estimates were comparable in magnitude.
Among the additional variables assessed, premorbid adjustment and mode of onset were found to
be associated with global functioning. Results from our unadjusted models showed a statistically
significant relationship between global functioning and premorbid adjustment (β =-7.85, 95% CI:
-15.18 to -0.51), however when included within the fully adjusted model this relationship was
rendered no longer statistically significant. Mode of onset, although insignificant in our
unadjusted model however was significant within our fully adjusted model (β =-4.03, 95% CI: 7.86 to -0.19), demonstrating that when compared to those with an acute onset of psychosis,
individuals with an insidious onset of psychosis had poorer functioning overall.

4.5.1.2 Objective 2
Similar findings were observed between our main analyses (n=105) and our sensitivity analyses
(n=69) including four additional variables in regard to assessing each functional subdomain.
Findings for each of our three exposure variables were consistent with our main analyses across
functional subdomains. The magnitude of effect was smaller across all models with a narrower
confidence interval.
In regard to the functional subdomain of working productivity, our models did not show
evidence of a significant association between age of onset, mode of onset, duration of untreated
psychosis or premorbid adjustment with working productivity.
When assessing the functional subdomain of independent living and self-care, although our
unadjusted models showed age of onset and premorbid adjustment to be associated with
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independent living and self-care (β =0.05, 95% CI: -0.01 to 0.10; β =-2.13, 95% CI: -4.15 to 0.11), these associations did not hold in our full model.
Unadjusted models assessing the functional domain of immediate social networks showed a
significant association between the functional domain and premorbid adjustment (β =-2.37, 95%
CI: -4.22 to -0.53) however, this relationship did not remain statistically significant within the
full model. However, when controlling for the other identified factors, findings from our full
model showed mode of onset, being the manner in which psychotic symptoms evolve during the
first episode of psychosis, to be significantly correlated with the functional domain (β =-1.06,
95% CI: -2.07 to -0.05). Similar to our findings for immediate social networks, a significant
association between mode of onset and extended social networks was present within our full
model (β =-1.38, 95% CI: -2.51 to -0.25). Although age of onset was shown to be significant in
our unadjusted models, this relationship did not remain when controlling for other factors.

4.5.2 Sensitivity Analyses Treating Outcome as Ordinal
4.5.2.1 Objective 1
Results from our sensitivity analyses treating the outcome of global functioning as measured on
an ordinal scale found results consistent with our main analyses. Our exposure variables, being
self-efficacy, anticipatory pleasure capacity and defeatist performance beliefs, remained nonsignificant, although the magnitude of effect was smaller and had narrower associated
confidence intervals in comparison with our main analyses.

4.5.2.2 Objective 2
In contrast to the main analyses, results from the sensitivity analyses treating the four functional
subdomains, working productivity, independent living and self-care, immediate social networks
and extended social networks, as measured on an ordinal scale found a small but statistically
significant effect for self-efficacy with working productivity and extended social networks.
Specifically, an increase in self-efficacy was associated with a decrease in the odds of being in a
lower working productivity category, with an odds ratio of 0.91 (95% CI: 0.84 to 0.99), and a
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decrease in the odds of being in a lower functioning category in terms of extended social
networks with an odds ratio of 0.87 (95% CI: 0.80 to 0.95).
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Chapter 5
5 Discussion
In this concluding chapter, an overview of key study findings, by objective, will be discussed and
contextualized within the current evidence base. Section 5.1 will first discuss findings from our
analyses examining the correlation between measures of negative symptoms and functioning,
followed by a discussion of key findings from our linear regression models assessing the
relationship between drivers of motivation and functioning, adjusting for potential covariates.
Study strengths and limitations will then be discussed in Sections 5.2 and 5.3, respectively.
Finally, translation of results for clinicians and researchers will be discussed in Section 5.4,
followed by study conclusions in Section 5.5.

5.1 Overview of Findings
5.1.1 Correlational Analyses
In recent years, a number of studies have examined the relationship between psychotic
symptomatology and functional outcomes in individuals with psychotic disorders
20,26,27,29,71,74,92,170

. A relationship between negative symptoms and functional outcomes has been

consistently found, with avolition being shown to be the strongest correlate than any other
negative symptom subdomain. A 2012 study by Hunter and Barry investigated the relationship
between negative symptoms and functioning using multiple measures of functioning. Their
findings demonstrated strong, statistically significant correlations between the PANSS and five
of six measures of functioning assessed 64. These scales included the Global Assessment of
Functioning scale171, the Personal and Social Performance scale172, the Quality of Life Scale173,
the Functional Remission of General Schizophrenia scale174 and the Psychosocial Remission in
Schizophrenia scale175, as well as the Subjective Wellbeing under Neuroleptics scale176, which
did not significantly correlate with the PANSS scores. With findings such as these, conclusions
have been made that negative symptoms are predictive of functional outcomes, specifically with
motivational deficits being associated with poorer functioning. However, studies that found this
strong correlation have used measures to assess negative symptoms that, although extensively
used, do not discriminately measure the construct of negative symptoms separate from functional
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outcomes, calling into question the validity of these measures given our current knowledge of
negative symptoms. Specifically, when looking at the avolition sub-domain of the commonly
used SANS, we see a high degree of overlap between the questions posed to assess one’s degree
of avolition and measures used to assess functioning itself, as discussed in Chapter 2. For
example, the ability to care for one’s self in terms of grooming habits is considered a behavioral
marker of functioning within the independent living and self-care domain of the RFS however it
is also measured as part of the avolition sub-domain of the SANS as a behavioral marker of poor
motivation (Appendix B and C). The questions posed to assess avolition fail to truly measure
factors related to motivation and focus more on overt behavioral outcomes believed to be
indicative of underlying motivation. Current measures of negative symptoms tap into behavioral
achievement rather than the symptom itself and possibly fail to adequately address more
experiential motivational deficits 9, which has been recognized as a limitation of current
assessments of negative symptom domains 29,71.
We conducted a series of Pearson correlation analyses to see whether this relationship was
present within our sample. Our analyses demonstrated moderate to strong, significant
correlations between all domains of negative symptoms and functional outcomes, consistent with
our hypothesis. Total scores on the SANS demonstrated a strong negative correlation to total
scores on the RFS (r = -0.737, p<0.001) as well as with each subdomain (Table 4.2).The largest
Pearson correlation coefficient was observed between the negative symptom domain of avolition
and global functioning (r = -0.754, p<0.001), consistent with our hypothesis that these two
domains would be highly correlated due to the high degree of overlap between measures.
Although our correlations are consistent with ongoing discussions on measures of avolition and
negative symptoms 23,25-27,29,71-74, we proposed that this association is present due to both
domains measuring the same underlying constructs. We believe that our current method of
measuring avolition may be erroneously connected to functioning due to the focus on assessing
avolition using overt behavioral markers such as grooming habits and difficulty obtaining or
maintaining employment - factors that are similarly found within scales assessing functioning. In
other words, the strong relationship between negative symptoms, namely avolition, and
functional outcomes that has been observed in the literature to date may be due to the two
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domains being assessed using similar indicators, resulting in erroneous conclusions formed
regarding the role of avolition as a predictor of functional outcomes. Through the literature we
identified 3 psychological drivers of motivation that assess intrinsic motivational drivers rather
than overt behavioral characteristics. Our correlation analyses demonstrated small yet significant
relationships between all three of the drivers and avolition. As well, we observed differences
between the motivational drivers and specific functional subdomains, in that certain
psychological drivers of motivation were found to have significant associations with one or two
functional subdomains rather than all four.

5.1.2 Objective 1
Although recent studies have recognized the issues associated with current measures of avolition
in addition to other negative symptoms 29,71, no study to date has directly assessed the influence
of motivational factors on functional outcomes, excluding negative symptoms scales. In order to
better understand the relationship between avolition and functioning, we aimed to investigate
whether drivers of motivation were associated with overall functional capacity in a sample of
individuals with psychotic disorders. We had hypothesized that, given the existing literature
showing that avolition has a dominant role in the development of poor functional outcomes, our
identified drivers of motivation would each demonstrate a statistically significant association
with overall functioning, namely that both self-efficacy and anticipatory pleasure capacity would
have a significant, positive relationship with overall functioning, and defeatist performance
beliefs would exhibit a significant, negative relationship with overall functioning.
When assessing the relationship between the identified drivers of motivation and functioning, we
found that each of the drivers assessed had a small but statistically significant relationship with
overall functioning. However, when adjusting for our covariates, contrary to our hypothesis, we
did not observe any statistically significant relationships between any of the motivational drivers
and overall functioning in our fully adjusted model. Our findings therefore seem to be in
disagreement with the current evidence base, in that our identified exposure variables, being
considered primary indicators of motivation and therefore avolition, were not significantly
associated with functioning in our multivariable analyses.
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Comparison of our findings to past research assessing functional outcomes suggest that there is a
possibility that the previously observed relationship between functioning and avolition was
falsely identified due to the overlap between measures of negative symptoms and functioning.
Given that our identified drivers of motivation can influence one’s degree of motivational
deficits and therefore levels of avolition, it would stand to reason that if avolition and functional
outcomes were associated with one another, then this relationship would still be observed via
these motivational drivers. Buck and Lysaker 110 found that anticipatory pleasure deficits at
baseline, as measured by the TEPS, was linked to poorer levels of interpersonal relations at 6month follow up among people with schizophrenia or schizoaffective disorder (n=51). As well,
Ventura and Colleagues 28 conducted a study assessing the relationship between negative
symptoms, neurocognition, and daily functioning along with what they termed “attitudinal
beliefs” which included self-efficacy and defeatist performance beliefs. They also found strong
correlations between self-efficacy and defeatist performance beliefs and global functioning.
However, these analyses were univariate and failed to assess motivational drivers while
controlling for confounding factors, which may explain the discrepancies between with our
findings. Other studies using these drivers of motivation have conducted mediation analyses
using negative symptoms as mediators in the relationship between motivational drivers and
functioning. Ventura and colleagues 28conducted one such analysis, where self-efficacy and
defeatist performance beliefs were assessed for their indirect effect on functioning via negative
symptoms. They found evidence consistent with a model where self-efficacy and defeatist
performance beliefs, referred to as ‘dysfunctional attitudes’, had a partial influence on negative
symptoms which in turn significantly influenced daily functioning levels. However, as with the
previously stated analyses, no confounding factors were assessed which would likely affect study
results, as observed in our analyses where the inclusion of covariates rendered the relationship
between drivers of motivation and functioning non-significant. As well, given that these analyses
included measures of negative symptoms, which we have shown overlap significantly with
functional outcomes, it is possible that these previous findings were inflated.
Although we found no significant relationship between overall functioning and any driver of
motivation, results demonstrated that when adjusting for our covariate variables, total years of
education and alcohol use exhibited a significant relationship with overall functioning. The
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finding of education being significantly associated with overall functioning is consistent with
findings reported by Santesteban-Echarri and colleagues,20 who conducted a meta-analysis
assessing predictors of functional recovery in individuals with a first-episode of psychosis, with
education being a significant correlate of functioning in 15 of 22 studies examining this variable
(r=0.16, 95% CI: 0.11 to 0.20, p<0.00). Taken together, these findings suggest that one’s level
of education is related to overall functioning and that this association reflects a positive
relationship between the two variables.
Interestingly, alcohol usage below what is considered alcohol abuse, in comparison to
individuals that reported no alcohol use, was found to have a significant, positive relationship
with overall functioning, with individuals reporting some alcohol usage experiencing better
overall functioning then those who reported no alcohol use. Although our measure of alcohol use
was self-reported, similar findings have been reported with substance use177. Similar to our
findings, Swartz and colleagues 177found that compared to individuals who were abstinent, those
who used substances (alcohol or illicit drugs) without serious impairment or without diagnosis of
a substance use disorder had higher overall psychosocial functioning and equivalent functioning.
One potential explanation for these counterintuitive findings is that some degree of initiative,
social contact, and organizational skills are required for engaging drug-involved peer and
obtaining illicit substances 177.

5.1.3 Objective 2
To our knowledge, no study to date has examined the relationship between motivational drivers
and specific subdomains of functioning. We hypothesized that each driver of motivation would
have a different relationship with functioning; however, our results showed no statistically
significant relationships between any of our drivers of motivation across all functioning
subdomains when adjusting for possible covariate factors. Interestingly, we did find differences
in our unadjusted models. Self-efficacy, when not controlling for other variables, was found to
be significantly correlated with both of the functional subdomains of working productivity and
extended social networks. In our sensitivity analyses, these relationships remained significant
within our fully adjusted model however effect sizes were small. Defeatist performance beliefs
were the only motivational driver that was found to be correlated with the functional domain of
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independent living and self-care. Defeatist performance beliefs were also found to have a
significant association with extended social network functioning. Anticipatory pleasure capacity
was found to be significantly associated with both immediate and extended social network
subdomains. Therefore, although our fully adjusted models did not find significant associated
between these variables and functioning, we did observe differences between drivers of
motivation and functional subdomains.
A number of covariates were found to be associated with the functional subdomains. Both
alcohol use and drug use were found to be significantly associated with the functional subdomain
of independent living and self-care. Education, social support, and alcohol use were found to
have significant associations with the functional subdomain of immediate social networks.
However, when assessing extended social networks, only education was found to be significantly
correlated with functioning. Overall, education was shown to have the strongest relationship with
functioning; being significantly correlated with overall functioning as well as 3 out of 4
subdomains of functional outcomes.
Our main analyses identified small yet significant relationships between all of our drivers of
motivation and overall functioning within our unadjusted models, however we did not find a
statistically significant relationship between the identified drivers of motivation and functioning
after adjusting for covariates. Similar findings were shown in our models of each functional
subdomains, with some drivers of motivation being shown to have a small but significant
relationship to that functional domain. Our findings, although the first to assess these factors in
conjunction with possible covariate factors and without the influence of negative symptoms,
goes against previous studies of functional outcomes within a psychosis population. The current
evidence base suggests that negative symptoms play an important role in the development of
poor functional outcomes. However, our exposure variables, recognized to be factors that
influence or “drive” motivation and therefore theoretically should be a direct influence on
avolition, failed to support this theory. Self-efficacy, anticipatory pleasure capacity, and defeatist
performance beliefs, although each identified as motivational targets, did not support the theory
that avolition leads to poor functional outcomes. Therefore, our findings seem to propose that the
previously observed relationship between negative symptoms, mainly avolition, and functional
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outcomes may be inflated due to the overlapping measures used to measure these constructs and
the lack of control for additional factors.

5.2 Study Strengths
This study had a number of strengths. Firstly, to our knowledge this was the first study to assess
the relationship between functioning and avolition using measures that directly assess factors
known to drive motivation. This effectively allowed for us to observe the relationship between
motivation and functioning without overlapping measures which we believe has previously
resulted in an inflated association between negative symptoms and functioning. Our study was
unique in the consideration of multiple driving factors of motivation rather than a single factor.
This allowed us to first assess whether there was in fact a relationship between motivation and
functioning, and to ascertain whether certain factors exerted a stronger influence than others.
In contrast to previous studies assessing functional outcomes, we also included a number of
potential covariate factors, including sociodemographic and clinical factors. Although a number
of studies have been conducted assessing the relationship between negative symptoms and
functioning and have found a significant relationship between the two, the majority of these
studies did not include a wide range of potential covariates variables, and instead included other
symptom domains such as positive symptoms and affective symptoms 26,28,29,71,110,170. Given that
our literature search identified a number of factors that influence functioning, it is important to
account for these factors in order to truly assess the relationship between motivation and
functioning. Accounting for covariate variables is an important strength to this study as the
factors found to be associated with functional outcomes across our models were variables
identified as covariates and not our exposure variables. This illustrates that the strongest
relationships with functioning were not found with motivational factors but rather variables such
as education, length of treatment, alcohol use and drug use. As well, these variables were all
analyzed using a series of simple and multivariable linear regression analyses, allowing for us to
assess and estimate the independent effect of our exposure variables (self-efficacy, anticipatory
pleasure capacity and defeatist performance beliefs), controlling for each other and for our
identified potential covariates. Furthermore, the selection of covariates included within our

79

analyses were guided by our research using previous studies that make up the current evidence
base.
Lastly, we also re-assessed our findings for robustness by means of two sensitivity analyses.
Given that our outcome of functioning is assessed on a Likert scale, we additionally ran our
analyses using an ordinal logistic regression model to assess whether treating our outcome as
continuous had affected our results. As well, we used a subset of our total sample to re-assess our
exposure variables controlling for four additional variables that we had identified as possible
covariates. Both sensitivity analyses were consistent with our main analyses, demonstrating the
robustness of findings for this study.

5.3 Study Limitations
Although our study had a number of strengths, there were also some limitations that should be
considered. This study design was cross-sectional, with data collection for each participant
occurring at one time point. Findings from cross-sectional research is limited when discussing
directionality of hypotheses. While the presence of associations, and whether they are positive or
negative in nature, can be discussed, the directionality of these associations cannot be determined
and any consideration of variables as cause and effect are solely theoretical in nature.
Specifically, we cannot determine whether these motivational drivers impact functioning or
whether poor functioning impacts motivation. Although we were able to show associations, or
lack of, between our exposure variables and outcomes, cross-sectional research is also limited in
regard to the statements and conclusions made when discussing causality. Longitudinal models
would be better able to assess causality, namely, whether drivers of motivation have a causal role
in functional outcomes. In previous studies, self-efficacy and defeatist performance beliefs have
been identified as being fluid, with the possibility of change occurring over time. Given this
understanding that motivational drivers are not stagnant and therefore motivational level can
change, our cross-sectional study only pinpoints motivation at one time point. A longitudinal
study assessing motivational drivers and functioning over time would allow one to form more
concrete conclusions on the relationship between motivation and functioning in psychosis
populations. We also acknowledge that the drivers of motivation were all assessed using selfreport measures and therefore may be influenced by response biases and/or factors affecting their
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current mindset at the time of assessment such as a recent psychotic episode or increases in
depressive symptoms.
Furthermore, within our analyses we controlled for a number of covariates, with a few factors
being found to have a significant association with functional outcomes. Although we controlled
for these factors, based on our literature review which demonstrated their association with
functional outcomes, as with our drivers of motivation we cannot determine the directionality of
these variables in regard to both motivation and functioning. We chose to examine the direct
effect of motivational drivers on functional outcomes, given the current discussion on avolition
being the strongest influence on functioning. However, education was found to be significantly
associated with overall functioning within our sample, and when included within our fully
adjusted model this covariate remained significant while our motivational drivers did not. One
could argue that motivational drivers may impact educational achievement, and consequently
influence functional outcomes; thereby acting as a mediator in this relationship, or, that
educational achievements may impact motivational drive, in turn affecting functioning.
Therefore, there is a possibility that some of our covariates, such as education, depression or
social support, may have a more integrated role within the causal pathway between motivational
drivers and functioning, and that their inclusion within our fully-adjusted model resulted in overadjustment. However as indicated in Tables 4.3 to 4.7, our model diagnostics demonstrated that
the R2 values calculated for each regression model ranged between 0.27 and 0.34 depending on
the model; demonstrating that approximately 27% to 34% of the total variance was accounted for
by our motivational drivers and covariates. Given that only a small proportion of the variance in
functional outcomes was accounted for by the motivational drivers and covariates, there may be
other factors that were not included within our models that may play an important role in the
development of poor functional outcomes. Further research should consider these possibilities,
namely through a longitudinal study design to aid the discussion on possible mediational roles
within the causal pathway.
It should also be noted that our study was conducted using a sample that had been previously
receiving treatment. The duration of untreated psychosis within a subset of our sample had a
median value of 23.1weeks (IQR= 52.4), meaning that from the first signs of psychosis over half
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of participants did not start receiving treatment for close to 6 months. Duration of untreated
psychosis has been shown to be associated with poorer symptomatology and social functioning
16,20

. Given that early psychosis treatment is associated with numerous benefits in terms of

symptomatic recovery, reduced risk of relapse and a better ability to preserve and develop
psychosocial skills, it is possible that our results may be indicative of a more chronic population
and not be generalizable to individuals who are first starting treatment.
Additionally, our study sample was recruited from an early psychosis intervention program that
had their own inclusion criteria, and the majority of study participants were male and Caucasian.
Therefore, our conclusions may be limited to these clinical and demographic populations.
Specifically, our findings may not be generalizable to individuals receiving treatment in other
settings, females, individuals with affective psychotic disorders, or other ethnic minority groups
who may face additional socio-economic barriers in regard to functioning. Notably, our study
population also exhibited moderately high functioning with median global functioning scores of
22 out of a possible score of 28. It is therefore possible that our study findings would not be
generalizable to a more functionally-heterogeneous population. Future studies should address
these limitations in more diverse samples.
Although our sample was relatively large given the population and previous studies in the same
field, our sample only included 105 participants whose data were used for our main analyses.
However, within this sample we had to exclude data on four variables we identified as possible
covariates, including age of onset, duration of untreated psychosis, premorbid adjustment and
mode of onset. These variables were excluded from our main analyses because they were not
assessed for the subset of our sample that were enrolled in the negative symptom study and
therefore were assumed to be Missing Not at Random. This prohibited us from imputing these
variables, given that the mechanism of missing data required for multiple imputation is for data
to be Missing at Random. Although we were able to include these four variables in our
sensitivity analyses, our sample size was reduced to include only those participants who were
enrolled in the 10-year outcome study, a total of 69 individuals. Furthermore, given that we had a
small sample size and controlled for a number of covariates, there is a possibility that we overfitted our models resulting in misleading findings regarding the relationship between our
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identified drivers of motivation and functioning. The use of a small sample size for our main
analyses, and a loss of sample size for our sensitivity analysis, reduces our statistical power,
therefore further research on the topic using a larger sample size is needed.

5.4 Study Implications and Future Directions
The current evidence base suggests that negative symptoms, more so than any other factor, are
significantly associated with level of functioning, both in the early stages of illness and in more
chronic populations. However, our study using more intrinsic measures of motivation rather than
measures of avolition, failed to support these findings and lends credence to the growing opinion
that the current measurement of avolition specifically, and negative symptoms more broadly, is
lacking. This calls for a greater recognition that there are other factors that may play a role in the
extent of poor functioning observed within populations with psychosis. A growing evidence base
has suggested that neurocognition is strongly associated with functional outcomes 178-182.
Furthermore, a relationship between motivational deficits, neurocognitive elements and
functioning has been proposed, with motivational deficits and neurocognitive factors influencing
functional outcomes 183,184. Within our study, we focused on negative symptoms primarily and
excluded neurocognitive variables; however, given that our analyses did not find a relationship
between motivational drivers and functioning, future research should build upon past studies
assessing the relationship between neurocognitive variables and functioning.
Our study was the first to assess a number of different motivational factors and their relationship
with functional outcomes, however, there are other possible factors that may influence one’s
motivation level. Alternative variables such as self-stigma and fear of negative evaluations from
others could affect one’s perception of ability in regard to goal achievement. Therefore, future
research should address other types of motivational influences to form a better understanding of
the impact of motivation on functioning.
As well, our analyses showed that education, social support, and alcohol use were associated
with functioning, highlighting the important role of social determinants on health outcomes. This
reflects the need to also address recovery through socioeconomic engagement and participation,
as well as the future development and implementation of health and social policy initiatives to
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address the socioeconomic and health inequalities observed within psychosis populations 185,186.
Enhancement of social participation, through engagement with community activities and
connecting individuals with peer groups to form social support networks and develop social
skills, in combination with current pharmacological/psychological treatment methods may
provide additional benefits in regard to recovery, both symptomatic and functional.
Importantly, findings from this study demonstrate a need for updated measures of avolition and
negative symptoms. With motivational drive being composed of multiple factors, both intrinsic
and extrinsic, there is a need for measures to include a broader assessment of motivational
influences. Furthermore, the development of these measures should be conducted in a manner
that takes into account the individual experiences of motivation, and what drives motivation,
from individuals with experiences of avolition.

5.5 Conclusions
To our knowledge, this study was the first to assess the relationship between multiple drivers of
motivation and functioning among people with psychotic disorders, in addition to formally
recognizing the overlap between measures of negative symptoms and functioning. Findings from
our study suggest that the relationship between avolition and negative symptoms may be
artificially inflated due to the way avolition is measured, given that our more intrinsic measures
of motivation failed to find effects similar to past studies that employed the use of avolition
measures that overlapped with functioning measures. Other social determinants, such as
education, substance use, and social support, were shown to have a stronger relationship with
functioning, more so than any other factor included within our models. Further research
examining drivers of motivation within a large prospective dataset is necessary to solidify our
understanding regarding the influence of motivational drivers on functional outcomes.
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Appendix A. Copies of Western REB Approval
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11.

12.

Blocking
The patient indicates, either spontaneously or with prompting, that
his or her train of thought was interrupted.

0

Increased Latency of Response
The patient takes a long time to reply to questions; prompting
indicates the patient is aware of the question.

0

1

2

3

4

5
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Appendix B. Scale for the Assessment of Negative Symptoms -Avolition/Apathy and
Anhedonia/Asociality
Subdomains
13.
Global Rating
of Affective Flattening

0

1

2

3

4

5

This rating should focus on overall severity of symptoms,
especially unresponsiveness, eye contact, facial expression and
vocal inflections.

AVOLITION - APATHY
14.

Grooming and Hygiene
The patient’s clothes may be sloppy or soiled, and he or she may have
greasy hair, body odour, etc.

0

1

2

3

4

5

15.

Impersistence at Work or School
The patient has difficulty seeking or maintaining employment,
Completing school work, keeping house, etc. If an inpatient, cannot
persist at ward activities, such as OT, playing cards, etc.

0

1

2

3

4

5

16.

Physical Anergia
The patient tends to be physically inert. He or she may sit for hours
and not initiate spontaneous activity.

0

1

2

3

4

5

17.

Global Rating of Avolition - Apathy
Strong weight may be given to one or two prominent symptoms
if particularly striking.

0

1

2

3

4

5

ANHEDONIA – ASOCIALITY
18.

Recreational Interests and Activities
The patient may have few or no interests. Both the quality and
quantity of interests should be taken into account.

0

1

2

3

4

5

19.

Sexual Activity
The patient may show decrease in sexual interest and activity,
or enjoyment when active.

0

1

2

3

4

5

20.

Ability to Feel Intimacy and Closeness
The patient may display an inability to form close or intimate
relationships, especially with opposite sex and family.

0

1

2

3

4

5

21.

Relationships with Friends and Peers
The patient may have few or no friends and may prefer to spend
all of his her or her time isolated.

0

1

2

3

4

5

22.

Global Rating of Anhedonia - Asociality
This rating should reflect overall severity, taking into account the
patient’s age, family status, etc.

0

1

2

3

4

5

Scale for the Assessment of Negative Symptoms (SANS)

Page 2
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Appendix C. Role Functioning Scale
ROLE FUNCTIONING SCALE (Goodman et al., 1993)
ID # _____________________

Score

1

2

3

4

5

6

7

Working Productivity

Independent Living, Self Care

Rate the client primarily in the most
appropriate expected role (i.e.,
homemaker, student, wage earner)

(Management of household, eating,
sleeping, hygiene care)

Productivity severely limited; often
unable to work or adapt to school or
homemaking; virtually no skills or
attempts to be productive

Lacking self-care skills approaching life
endangering threat; often involves
multiple and lengthy hospital services;
not physically able to participate in
running a household

Occasional attempts at productivity
unsuccessfully; productive only with
constant supervision in sheltered work,
home or special classes.

Marked limitations in selfcare/independent living; often involving
constant supervision in or out of
protective environment (e.g., frequent
utilization of crisis services).
Limited self-care/independent living
skills; often relying on mental/physical
health care; limited participation in
running household.

Limited productivity; often with
restricted skills/abilities for
homemaking, school, independent
employment (e.g., requires highly
structured routine).
Marginal productivity (e.g., productive
in sheltered work or minimally
productive in independent work;
fluctuates at home, in school; frequent
job changes).
Moderately functional in independent
employment, at home or in school.
(Consider very spotty work history or
fluctuations in home, in school with
extended periods of success.)
Adequate functioning in independent
employment, home or school; often not
applying all available skills/abilities.

Optimally performs homemaking,
school tasks or employment-related
functions with ease and efficiency.

Marginally self-sufficient; often uses
REGULAR assistance to maintain selfcare/ independent functioning;
minimally participates in running
household.
Moderately self-sufficient; i.e., living
independently with ROUTINE
assistance (e.g., home visits by nurses,
other helping persons, in private or selfhelp residences).
Adequate independent living & selfcare with MINIMAL support (e.g., some
transportation, shopping assistance
with neighbours, friends, other helping
persons).
Optimal care of health/hygiene,
independently manages to meet
personal needs and household tasks.

DATE: _________________________

Immediate Social Network
Relationships
(Close friends, Spouse, Family)

Extended Social Network
Relationships
(Neighbourhood, community
church, clubs, agencies, recreational
activities)

Severely deviant behaviours within
immediate social networks (i.e., often
with imminent physical aggression or
abuse to others, or severely withdrawn
from close friends, spouse, family; often
rejected by immediate social network)
Marked limitations in immediate
interpersonal relationships (e.g.
excessive dependency or destructive
communication or behaviours).

Severely deviant behaviours within
extended social networks (i.e., overtly
disruptive, often leading to rejection by
extended social networks).

Limited interpersonally; often no
significant participation/
communication with immediate social
network.

Limited range of successful and
appropriate interactions in extended
social networks (i.e., often restricts
community involvement to minimal
survival level interactions).

Marginal functioning with immediate
social network (i.e., relationships are
often minimal and fluctuate in quality).

Marginally effective interactions; often
in a structured environment; may
receive multiple public system support
in accord with multiple needs.

Moderately affective continuing and
close relationship with at least one other
person.

Moderately affective and independent
in community interactions; may receive
some public support in accord with
need.

Adequate personal relationship with
one or more immediate members of
social network (e.g., friend or family).

Adequately interacts in neighbourhood
or with at least one community or other
organization or recreational activity.

Positive relationships with spouse or
family and friends; assertively
contributes to these relationships.

Positively interacts in community;
church or clubs, recreational activities,
hobbies or personal interests, often with
other participants.

Often totally isolated from extended
social networks, refusing community
involvement or belligerent to helpers,
neighbours, etc.
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Appendix D. Additional Information Pertaining to the Psychosis and Early Intervention
Programme (PEPP) Services
After admission, an individualized treatment plan is developed in collaboration with the client,
and whenever possible, their family 121. Treatment plans are based on an assertive case
management model which involve both medication management, involving the initiation of
antipsychotic medication combined with psychosocial management, such as family
interventions, group interventions, and individualized therapies provided by a nurse or case
manager 120,121. Case managers assess, treat, and work through the patient’s recovery from
psychosis which is achieved through working closely with patients and their families with the
aim to reintegrate the patient to his or her full potential over a two-year period120,121. Patients
may stay in this core intensive treatment programme for a minimum of two years with patients
not recovered sufficiently to assume independent functioning and/or not in remission being
provided with extended case management for an additional one to three years 14,120. However, the
majority of patients graduate from this programme. All patients will continue with medical
management with their respective psychiatrists for up to a total of five years with most patients
being seen every one to three months while stable120,121.
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Appendix E. Anticipatory Pleasure Subdomain Questions of the TEPS
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108

109

Appendix F. Additional Covariate Variables
Age of Onset
Age of onset refers to one’s chronological age at the time of the first onset of psychotic
symptoms, with psychotic symptoms being identified by hallucinations, delusions or gross
disorganization 187. A younger age of onset has been found to be associated with poorer
premorbid functioning 188 however, findings are mixed regarding the effect a younger age of
onset has on functional outcomes 131,132,137,189-191. Age of onset was calculated via the
Topography of Psychotic Episode (TOPE) section of the Course of Onset and Relapse Schedule
(CORS)192, a structured interview that assesses lifetime history of illness prior to the onset of the
current psychotic episode, using date of birth and date of initial behavioral changes. The CORS
consists of 5 sections: (1) Identifying Information, (2) Demographic Information, (3) Family
Structure and Health, (4) Pathways to Care, and (5) Topography of Psychotic Episode.
The CORS was completed at baseline for the 10-year outcome study via information obtained
from family members and the referral source however, this measure was not used for the
negative symptom study. Given that a significant portion of our data set does not have data on
age of onset, we were unable to include the variable in our main multivariable regression
analyses and therefore only used the CORS as a continuous measure of age of onset for our
descriptive statistics and sensitivity analyses.
Mode of Onset
Mode of onset refers to how quickly psychotic symptoms evolve during the first episode of
psychosis 193. Mode of onset was calculated using the CORS by subtracting the date of onset of
psychosis from the date of initial behavioral changes.
The CORS was completed at baseline for the 10-year outcome study via information obtained
from family members and the referral source however, this measure was not used for the
negative symptom study. Given that a significant portion of our data set does not have data on
mode of onset, we were unable to include the variable in our multivariable regression analyses
and therefore only used the CORS as a dichotomous measure of mode of onset for our
descriptive statistics and sensitivity analyses, with participants being categorized as having either
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an acute or insidious mode of onset. An acute mode of onset was defined as a period of less than
or equal to one month, whereas an insidious mode of onset was defined as more than one month.
In individuals with psychotic disorders, an insidious onset of psychosis is associated with a
greater duration of untreated psychosis 194and poorer functional outcomes193.
Duration of Untreated Psychosis
Duration of untreated psychosis was defined as the length of time, in weeks, from the onset of
psychotic symptoms (e.g. hallucinations) to the date of two months post initiation of
antipsychotic therapy. Information regarding the date of onset of symptoms and date of treatment
were obtained from the CORS at baseline for the 10-year outcome study. Duration of untreated
psychosis has been found to be associated with greater symptom severity 195,196, an insidious
mode of onset 194, and poorer functional outcomes 16,20,195,196.
The CORS has demonstrated high inter-rater reliability (ICC=0.86 to 0.90) for its ability to
calculate duration of untreated psychosis 197 and has been used in studies of participants with a
first episode of psychosis 198-200. Duration of untreated psychosis was treated as a continuous
variable.
Given that a significant portion of our data set does not have data on duration of untreated
psychosis, we were unable to include the variable in our multivariable regression analyses and
therefore only used the CORS as a continuous measure of duration of untreated psychosis for our
descriptive statistics and sensitivity analyses.
Premorbid Adjustment
Premorbid adjustment refers to one’s psychosocial functioning prior to the onset of psychotic
symptoms and was assessed using the Premorbid Adjustment Scale (PAS) 201 at baseline for the
10-year outcome study. The PAS is a series of rating scales that evaluate five domains of
functioning: (1) Sociability and Withdrawal, (2) Peer Relationships, (3) Scholastic
Performance, (4) Adaptation to School, and (5) Social-sexual Aspects of Life. All or some of
these domains of functioning are then assessed over four separate life periods including
childhood (up to age 11), early adolescence (12 to 15), late adolescence (17 to 18) and adulthood
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(19 and above). Social-sexual aspects of life is not assessed during the childhood life period,
along with scholastic performance and adaptation to school being not assessed during the
adulthood life period. Along with the four separate life periods, there is a general section which
assesses variables including education, employment, school, establishment of independence,
highest level of functioning, social-personal adjustment, degree of interest in life and energy
level.
Given that onset of illness typically occurs within the late adolescence and adulthood periods,
these sections were excluded from our analyses to reduce the effects of confounding 187.
Therefore, the ratings from the childhood and early adolescence periods were the section used
for our analyses to assess premorbid adjustment. Each item of this scale is rated using a Likerttype scale with responses ranging from 0 to 6. To calculate total scores for each psychosocial
domain, ratings were summed for all items and divided by the total possible score, which
resulted in total scores ranging from 0 to 6, with higher scores being indicative of worse
adjustment. For all ratings, the premorbid period was used as a reference frame 201. Information
on psychosocial functioning during this period was obtained from patient reports and reports
from family members. Poorer premorbid functioning is associated with greater negative
symptom severity 137,189,196,202, amotivation 141and poorer functional outcomes 20,130,132,137,202,203.
Brill and colleagues conducted a study to test the predictive and concurrent validity of the PAS
within a sample of 91 males diagnosed with either schizophrenia or schizoaffective disorder204.
Their findings demonstrate a high degree of correlation between the PAS late adolescence scores
and Draft Board assessments at age 17 years in terms of estimating premorbid functioning in
schizophrenic persons. The correlation of the PAS in terms of school achievements and school
adjustment items with the Draft Board assessments for functioning in structured environments
were r=0.71 and r=0.72, respectively, for concurrent ratings and r=0.4 and r=0.47, respectively
for the ratings obtained at the age of 17 204. The PAS was also found to have good reliability with
a weighted ICC for absolute agreement and consistency of 0.77 204.
For our analyses, we used the total premorbid adjustment scale rating for the childhood and early
adolescence period and treated the score as a continuous variable for our descriptive statistics
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and sensitivity analyses. However, we were unable to include the variable in our main
multivariable regression analyses due to its exclusion in the negative symptom study resulting in
a high degree of missing data and overall lack of variability within our data set.
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